<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lancet Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>The Lancet. Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1473-3099</issn><issn pub-type="epub">1474-4457</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8694750</article-id><article-id pub-id-type="pmcid-ver">PMC8694750.1</article-id><article-id pub-id-type="pmcaid">8694750</article-id><article-id pub-id-type="pmcaiid">8694750</article-id><article-id pub-id-type="pmid">34735799</article-id><article-id pub-id-type="doi">10.1016/S1473-3099(21)00400-X</article-id><article-id pub-id-type="pii">S1473-3099(21)00400-X</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Medical countermeasures against henipaviruses: a review and public health perspective</article-title></title-group><contrib-group><contrib contrib-type="author" id="au10"><name name-style="western"><surname>G&#243;mez Rom&#225;n</surname><given-names initials="R">Ra&#250;l</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Tornieporth</surname><given-names initials="N">Nadia</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au30"><name name-style="western"><surname>Cherian</surname><given-names initials="NG">Neil George</given-names></name><degrees>MBBS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au40"><name name-style="western"><surname>Shurtleff</surname><given-names initials="AC">Amy C</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au50"><name name-style="western"><surname>L&#8217;Azou Jackson</surname><given-names initials="M">Ma&#239;na</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au60"><name name-style="western"><surname>Yeskey</surname><given-names initials="D">Debra</given-names></name><degrees>PharmD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au70"><name name-style="western"><surname>Hacker</surname><given-names initials="A">Adam</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au80"><name name-style="western"><surname>Mungai</surname><given-names initials="E">Eric</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au90"><name name-style="western"><surname>Le</surname><given-names initials="TT">Tung Thanh</given-names></name><degrees>MSc</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway</aff><aff id="aff2"><label>b</label>University of Applied Sciences &amp; Arts, Hanover, Germany</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Mr Tung Thanh Le, Coalition for Epidemic Preparedness Innovations (CEPI), Marcus Thranes Gate 2, 0473 Oslo, Norway</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>1</day><month>11</month><year>2021</year></pub-date><volume>22</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">396304</issue-id><fpage>e13</fpage><lpage>e27</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>23</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-13 21:25:23.040"><day>13</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Published by Elsevier Ltd.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ceab10"><p>Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="cesec10"><title>Introduction</title><p id="para10">Nipah and other henipaviral diseases are listed among the WHO research and development blueprint priority diseases that pose a substantial public health risk because of their epidemic or pandemic potential and the absence of specific medical countermeasures to control and mitigate them.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Like other viruses of the henipavirus genus, Nipah virus (NiV) and Hendra virus (HeV) are zoonotic viruses that can spillover from <italic toggle="yes">Pteropus</italic> spp bats&#8212;their natural hosts and reservoir&#8212;to other mammals including humans.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Transmission occurs via exposure to animal or human secretions or respiratory droplets.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Human infections with NiV were originally described as a syndrome of fever and rapid neurological decline (ie, encephalitis) following contact with pigs. Since 2001, outbreaks (of Nipah virus Bangladesh strain [NiV-B]) report prominent respiratory symptoms (eg, atypical pneumonia and severe respiratory problems, including acute respiratory distress) and human-to-human transmission.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Since 1994, henipavirus spillover events have caused human outbreaks in several countries, including Australia, Bangladesh, India, Malaysia, the Philippines, and Singapore.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Although these outbreaks have thus far involved fewer than 1000 confirmed cases in total, the case&#8211;fatality rate for henipavirus infections can be as high as 100% depending on the context and constraints of the health-care systems where outbreaks occur. The geographical range where the various <italic toggle="yes">Pteropus</italic> bat species thrive is extensive<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> (encompassing Indo-Pacific territories across the southeast Asia and western Pacific regions) and covers half of the global population.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> In addition to the tragic loss of human lives, henipavirus outbreaks can generate fear, stigma, loss of livestock (pigs and horses), and have a negative economic effect on affected communities.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Although the reproduction number (<italic toggle="yes">R</italic>
<sub>0</sub>) for HeV has not been calculated, the <italic toggle="yes">R</italic>
<sub>0</sub> for NiV ranges from 0&#183;19 to 0&#183;59 in nosocomial settings or in the community, including corpse-to-person transmission.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>
</p><p id="para20">In an outbreak situation, use of widespread sensitive rapid diagnostic tests (RDTs)<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> combined with appropriate prevention and non-pharmaceutical intervention control measures, can rapidly lower the R<sub>0</sub>, buying precious time to deploy medical countermeasures. Vaccines, antivirals, and other medical countermeasures must be developed and made available for use worldwide, especially to populations at the highest risk of henipavirus infection.</p><p id="para30">
<boxed-text id="cetextbox10" position="float" orientation="portrait"><caption><title>Key messages</title></caption><p id="para40">
<list list-type="simple" id="celist10"><list-item id="celistitem10"><label>&#8226;</label><p id="para50">The pipeline for henipavirus countermeasures in development with clinical or preclinical data in the public domain includes at least eight small molecules, four monoclonal antibodies, and more than 15 vaccine candidates.</p></list-item><list-item id="celistitem20"><label>&#8226;</label><p id="para60">Several of these potential henipavirus medical countermeasures employ molecules, concepts, or technologies that are being used, where available, to treat or prevent COVID-19.</p></list-item><list-item id="celistitem30"><label>&#8226;</label><p id="para70">Access to henipavirus countermeasures will depend on various factors including cost and whether or not their use is authorised by the national regulatory authorities in henipavirus-affected countries.</p></list-item><list-item id="celistitem40"><label>&#8226;</label><p id="para80">Given the sporadic and unpredictable nature of current henipavirus outbreaks, traditional phase 3 clinical trial regulatory pathways might not be feasible for vaccines; thus, national regulatory authorities might have to rely on alternative regulatory pathways such as conditional market authorisation, authorisation under exceptional circumstances, or the animal rule.</p></list-item><list-item id="celistitem50"><label>&#8226;</label><p id="para90">To prepare for future henipavirus outbreaks, funding agencies, sponsors, and manufacturers of henipavirus medical countermeasures must jointly understand the regulatory requirements to apply for emergency use or relevant authorisation of henipavirus medical countermeasures in the affected countries where these measures are ultimately needed.</p></list-item><list-item id="celistitem60"><label>&#8226;</label><p id="para100">Lessons learned from the current COVID-19 pandemic provide a platform to connect with several stakeholders and to better prepare for future virus threats, including those posed by henipaviruses.</p></list-item></list>
</p></boxed-text>
</p><p id="para110">Internationally coordinated development of medical countermeasures against henipaviruses has mainly focused on NiV, but important progress has also been made in the development of such measures against HeV. Medical countermeasures against other henipaviruses have not been described. This Review will focus on publicly available evidence of potential medical countermeasures at any stage of development against both of these viruses. The aim is to provide a synthesis of available knowledge to aid epidemic preparedness. Potential costs and equitable access by all henipavirus-affected countries, including low-income and middle-income countries, are considered.</p></sec><sec id="cesec20"><title>Scope and search strategy</title><p id="para120">We reviewed information available in the public domain on therapeutics, monoclonal antibodies, and vaccine candidates evaluated for prophylaxis or protection, primarily against NiV and HeV infection, with a small amount of information found for other henipaviruses such as Cedar henipavirus, Ghanaian bat henipavirus, and Mojiang henipavirus. A targeted literature search was done in the English language following PRISMA guidelines and using &#8220;Nipah&#8221; OR &#8220;Hendra&#8221; OR &#8220;henipaviruses&#8221; as keywords with additional MeSH terms and selection criteria described in detail in the <xref rid="sec1" ref-type="sec">appendix p 1</xref>. Our search strategy did not include diagnostics. Although diagnostics are classified as medical countermeasures, they are mentioned here only in the context of other medical countermeasures. A detailed landscape analysis of the henipavirus diagnostic pipeline has been published elsewhere.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>
</p></sec><sec id="cesec30"><title>Evidence for medical countermeasures</title><sec id="cesec40"><title>Small molecules and antivirals</title><p id="para130">No approved therapy exists for henipavirus encephalitis, and a target product profile for potential NiV therapeutics is currently being developed by WHO.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Where available, intensive supportive therapy for severe respiratory and neurological complications is the current standard of care for individuals infected with henipavirus.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref> Further evidence is required to generate substantive guidance protocols for pre- and post-exposure prophylaxis against henipavirus encephalitis. Available evidence regarding potential therapeutics against henipavirus encephalitis is displayed in <xref rid="tbl1" ref-type="table">table 1</xref>
. Most of these compounds are broadly active antiviral therapeutics targeting a range of RNA and DNA viruses, rather than specifically developed as henipavirus medical countermeasures.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Available evidence on potential small molecules against henipavirus encephalitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>Classification</bold></th><th align="left" colspan="1" rowspan="1"><bold>Available evidence so far (route of therapeutic administration)</bold></th><th align="left" colspan="1" rowspan="1"><bold>Target</bold></th><th align="left" colspan="1" rowspan="1"><bold>Mode of action</bold></th><th align="left" colspan="1" rowspan="1"><bold>Finding</bold></th><th align="left" colspan="1" rowspan="1"><bold>Development or licensure status and indication</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Ribavirin<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">Open-label clinical trial in humans (oral and intravenous)</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Viral replication inhibition</td><td align="left" colspan="1" rowspan="1">Reduced mortality of treated patients compared with non-treated patients (by 36%)<xref rid="tbl1fn1" ref-type="table-fn">*</xref> in Malaysian outbreak (1998)</td><td align="left" colspan="1" rowspan="1">Approved for hepatis C virus and respiratory syncytial virus in several countries</td></tr><tr><td align="left" colspan="1" rowspan="1">Remdesivir<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">African green monkeys (intravenous)</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Nucleotide analogue prodrug, inhibits viral replication</td><td align="left" colspan="1" rowspan="1">Protection against viral challenge</td><td align="left" colspan="1" rowspan="1">Approved for COVID-19 by the US FDA. Emergency use authorisation for COVID-19 in Australia, Bangladesh, India, Singapore, Japan, Taiwan, and the European Union<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Favipiravir<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters (oral and subcutaneous)</td><td align="left" colspan="1" rowspan="1">NiV, HeV</td><td align="left" colspan="1" rowspan="1">Viral RNA-dependent RNA polymerase inhibitor</td><td align="left" colspan="1" rowspan="1">Protection against viral challenge</td><td align="left" colspan="1" rowspan="1">Approved for influenza A in japan, and for COVID-19 in several countries. Emergency use authorisation for COVID-19 in India<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Chloroquine<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref></td><td align="left" colspan="1" rowspan="1">Antimalarial</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters (intraperitoneal) and ferrets (route not stated)</td><td align="left" colspan="1" rowspan="1">NiV, HeV</td><td align="left" colspan="1" rowspan="1">Inhibition of F protein maturation</td><td align="left" colspan="1" rowspan="1">Inhibition of viral replication in vitro. No conclusive evidence in vivo challenge&#8212;in combination with ribavirin</td><td align="left" colspan="1" rowspan="1">Approved for malaria in several countries</td></tr><tr><td align="left" colspan="1" rowspan="1">Heparin<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></td><td align="left" colspan="1" rowspan="1">Anticoagulant</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters (subcutaneous)</td><td align="left" colspan="1" rowspan="1">NiV, HeV</td><td align="left" colspan="1" rowspan="1">Inhibits cell-mediated viral trans-infection by binding to heparan sulfate</td><td align="left" colspan="1" rowspan="1">Inhibition of viral trans-infection in vitro. Heparin treatment restricts NiV infection in Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">Approved for coagulopathies in several countries. Experimental: preclinical (Syrian golden hamster study)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rintatolimid<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref></td><td align="left" colspan="1" rowspan="1">Interferon inducer</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters (subcutaneous and intraperitoneal)</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Induces IFN-&#945; and IFN-&#946; production, inhibition of viral replication</td><td align="left" colspan="1" rowspan="1">Inhibition of viral replication and protection against viral challenge</td><td align="left" colspan="1" rowspan="1">Approved for chronic fatigue syndrome in Argentina. Experimental (phase 1 and 2 trials) for HIV and chronic fatigue syndrome<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Griffithsin<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral lectin</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters (intranasal)</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Inhibits viral entry, replication and syncytia formation</td><td align="left" colspan="1" rowspan="1">Reduced viral replication in vitro and provides partial protection against viral challenge</td><td align="left" colspan="1" rowspan="1">Experimental: phase 1 trials for HIV<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">VIKI-dPEG4-Toco, VIKI-PEG4-chol<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref></td><td align="left" colspan="1" rowspan="1">Viral fusion inhibitory peptide</td><td align="left" colspan="1" rowspan="1">African green monkeys and Syrian golden hamsters (intratracheal and intranasal)</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Inhibition of F protein fusion and cell entry</td><td align="left" colspan="1" rowspan="1">Partial protection against viral challenge</td><td align="left" colspan="1" rowspan="1">Experimental: preclinical</td></tr><tr><td align="left" colspan="1" rowspan="1">Gliotoxin<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref></td><td align="left" colspan="1" rowspan="1">Mycotoxin</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV, HeV</td><td align="left" colspan="1" rowspan="1">Viral RNA-dependent RNA polymerase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibition of infection and replication; Cytotoxic but possible topical applications</td><td align="left" colspan="1" rowspan="1">Experimental: exploratory</td></tr><tr><td align="left" colspan="1" rowspan="1">Bortezomib<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></td><td align="left" colspan="1" rowspan="1">Anticancer</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Proteasome inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibition of viral budding</td><td align="left" colspan="1" rowspan="1">Approved for multiple myeloma and mantle cell lymphoma by the US FDA</td></tr><tr><td align="left" colspan="1" rowspan="1">Balapiravir, R1479<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV, HeV</td><td align="left" colspan="1" rowspan="1">Viral RNA-dependent RNA polymerase inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibition of viral replication</td><td align="left" colspan="1" rowspan="1">Experimental, discontinued in phase 1 trials for dengue virus and hepatitis C virus<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Lumicitabine, ALS-8112<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Nucleotide analogue prodrug, inhibits viral replication</td><td align="left" colspan="1" rowspan="1">Inhibition of recombinant and wild-type NiV replication, and reduced NiV infectious virus titre</td><td align="left" colspan="1" rowspan="1">Experimental: phase 1 and phase 2 trials for respiratory syncytial virus<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">CH25H<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Intravenous-stimulated genes: catalyses oxidation of cholesterol to 25-hydroxycholesterol</td><td align="left" colspan="1" rowspan="1">Inhibition of viral membrane fusion and NiV replication</td><td align="left" colspan="1" rowspan="1">Experimental: exploratory</td></tr><tr><td align="left" colspan="1" rowspan="1">KIN1408<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref></td><td align="left" colspan="1" rowspan="1">Antiviral</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Immunomodulation of interferon regulatory factor 3</td><td align="left" colspan="1" rowspan="1">Inhibition of viral replication and decreased viral load in vitro</td><td align="left" colspan="1" rowspan="1">Experimental: exploratory</td></tr><tr><td align="left" colspan="1" rowspan="1">AB00991123, AB00992391, and AB00993210<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></td><td align="left" colspan="1" rowspan="1">Antivirals</td><td align="left" colspan="1" rowspan="1">In vitro</td><td align="left" colspan="1" rowspan="1">NiV</td><td align="left" colspan="1" rowspan="1">Sulfonamide compounds, unknown</td><td align="left" colspan="1" rowspan="1">Inhibition of NiV-induced cytopathic effect and virus replication</td><td align="left" colspan="1" rowspan="1">Experimental: exploratory</td></tr></tbody></table><table-wrap-foot><fn><p>HeV=Hendra virus. NiV=Nipah virus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn1"><label>*</label><p id="cenpara10">Patients also received intensive supportive treatment, and comparators were historical control patients.</p></fn></table-wrap-foot></table-wrap></p><p id="para140">Although some of the compounds listed in <xref rid="tbl1" ref-type="table">table 1</xref> are approved for other indications, none are yet WHO-prequalified for global procurement. Although a few of these have been shown to inhibit viral replication of henipaviruses in vitro and in vivo, there is still a paucity of evidence in animal models, partly due to the restricted access to biosafety level 4 (BSL4) laboratories required to do experiments. Thus, several research groups are doing in-silico analyses<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> or biosafety level 2 pseudotyped virus assays<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> to design and screen compounds for the potential treatment of henipavirus encephalitis before animal and clinical testing. Although animal challenge studies have mainly been against NiV, the evidence available for remdesivir, favipiravir, ribavirin, and griffithsin suggests that these agents could also offer broad protection against other henipaviruses (<xref rid="tbl1" ref-type="table">table 1</xref>). Only remdesivir and VIKI-dPEG-Toco are supported by non-human primate challenge data in African green monkeys, whereas all other experiments have been done in smaller animals such as mice, ferrets, or Syrian golden hamsters. Remdesivir has been shown to be protective against NiV challenge in African green monkeys when daily, intravenous treatment was initiated within 24 h of exposure to NiV and continued for 12 days.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Favipiravir has been shown to be protective in Syrian golden hamsters when given immediately after NiV infection.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Although these compounds have shown protection against challenge or post-exposure in animal models, demonstration of a therapeutic effect following symptom onset is still missing and merits further research.</p><p id="para150">For further development of these drugs as potential henipavirus medical countermeasures, additional pre-clinical and clinical studies are needed to determine the protective efficacy of the treatment regimen when initiated more than 24 h post-virus challenge, or even after symptom onset. Such studies will help define scenarios for prophylactic medical countermeasure use, as well as use of medical countermeasures as a post-infection intervention. The potentially narrow treatment window (within 24 h of exposure), timing of deployment, administration, and appropriate volumes of these products need to be considered for stockpiling. Notably, NiV can present with relapsing encephalitis,<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> and such cases might also benefit from antiviral prophylaxis.</p><p id="para160">Ribavirin (approved for hepatitis C virus) remains the only therapeutic with supportive evidence from a human outbreak;<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> mortality was reduced by 36% when ribavirin was used empirically in Malaysia during the outbreak of Nipah there in September, 1998&#8211;June, 1999.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> However, this evidence is limited due to the open-label nature of the study, the use of data from historical control patients who declined treatment or received standard treatment before ribavirin was available, and the simultaneous provision of intensive supportive care to patients. Ribavirin has since been used on a compassionate basis during the 2018 Indian outbreak of Nipah encephalitis<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib44" ref-type="bibr">44</xref> in which its use led to a possible reduction in viral load.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Soluble Ephrin-B2 receptors (EFBN2) have been shown to inhibit binding of NiV and HeV to target cells in vitro<italic toggle="yes">,</italic>
<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> but to our knowledge no EFBN2 analogues have been developed and specifically tested as potential therapeutics against henipaviruses.</p><p id="para170">A major bottleneck in moving promising compounds to clinical development is access to BSL4 facilities to conduct proof-of-concept challenge studies. Other key aspects for repurposed therapeutics include the need for further evidence on oral, intravenous, or intranasal routes of administration, the associated costs of intravenous administration, and the need for hospital infrastructure and supportive treatment. Regulatory requirements for repurposing approved medications, such as additional clinical trials for novel indications and reformulation of the product, must also be taken into account.</p></sec><sec id="cesec50"><title>Monoclonal antibodies</title><p id="para180">Monoclonal antibodies (mAbs) could be a viable medical countermeasure option for deployment under compassionate use for prophylaxis, and this might remain the case until a vaccine is available for emergency use or licensed. Similar to small molecules and antivirals, mAbs can potentially be used for both pre-exposure and post-exposure prophylaxis and fill in a critical gap before vaccine availability. mAbs may even be deployed in an emergency situation even after a vaccine becomes available, given that many of the vaccines follow a two-dose regimen and would require several days to elicit protective immunity. Four main mAb projects constitute the current landscape of mAbs under development against henipaviruses (<xref rid="tbl2" ref-type="table">table 2</xref>
). These mAbs have also been used as reagents to characterise antigens and inform vaccine design strategies.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Preclinical and clinical evidence for candidate monoclonal antibodies against henipaviruses</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>Evidence available</bold></th><th align="left" colspan="1" rowspan="1"><bold>Current development stage</bold></th><th align="left" colspan="1" rowspan="1"><bold>Target</bold></th><th align="left" colspan="1" rowspan="1"><bold>Developer</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">mAb 102&#183;4</td><td align="left" colspan="1" rowspan="1">Human (phase 1 trial), ferrets, and African green monkeys<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref></td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1">HeV or NiV G glycoprotein</td><td align="left" colspan="1" rowspan="1">Henry M Jackson Foundation for the Advancement of Military Medicine (Bethesda, MD, USA)</td></tr><tr><td align="left" colspan="1" rowspan="1">mAb 5B3, mAb h5B3&#183;1</td><td align="left" colspan="1" rowspan="1">Mice and ferrets<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref></td><td align="left" colspan="1" rowspan="1">Preclinical</td><td align="left" colspan="1" rowspan="1">HeV or NiV pre-fusion F glycoprotein</td><td align="left" colspan="1" rowspan="1">University of Washington (Seattle, WA, USA) and Uniformed Services University (Bethesda, MD, USA)</td></tr><tr><td align="left" colspan="1" rowspan="1">mAb HENV-26, mAb HENV-32</td><td align="left" colspan="1" rowspan="1">Ferrets<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref></td><td align="left" colspan="1" rowspan="1">Preclinical</td><td align="left" colspan="1" rowspan="1">HeV or NiV G glycoprotein (receptor-binding protein)</td><td align="left" colspan="1" rowspan="1">Vanderbilt Vaccine Center (Nashville, TN, USA)</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-G mAb, anti-F mAb</td><td align="left" colspan="1" rowspan="1">Hamsters<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></td><td align="left" colspan="1" rowspan="1">Preclinical</td><td align="left" colspan="1" rowspan="1">NiV G and F glycoprotein</td><td align="left" colspan="1" rowspan="1">INSERM (Paris, France), Universit&#233; Claude Bernard Lyon 1 (Lyon, France), and Institut Pasteur (Paris, France)</td></tr></tbody></table><table-wrap-foot><fn><p>HeV=Hendra virus. mAb=monocolonal antibody. NiV=Nipah virus.</p></fn></table-wrap-foot></table-wrap></p><p id="para190">mAb m102&#183;4 is the furthest in development and is the only NiV mAb with published phase 1 data. It has been shown to protect African green monkeys against challenge with both Malaysia and Bangladesh NiV strains.<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref> m102&#183;4 has been administered under compassionate use as post-exposure prophylaxis for HeV to 14 individuals in Australia and the USA.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> The phase 1 trial in Australia included 40 healthy adults, who received escalating single doses from 1 mg/kg to 20 mg/kg, or two 20 mg/kg infusions, 72 h apart, or placebo.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> No serious adverse events or adverse events leading to discontinuation were observed in this study. The most commonly reported adverse events included mild to moderate infections and infestations and headaches, occurring at a similar frequency in active treatment and placebo recipients. Another mAb, h5B3&#183;1 (ie, the humanised version of mAb 5B3 originally derived from mouse hybridoma 5B3), neutralises HeV and NiV Bangladesh and Malaysia strains and inhibits viral fusion in vitro<italic toggle="yes">.</italic>
<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> In NiV and HeV post-exposure prophylaxis models in ferrets, mAb h5B3&#183;1 protected animals against disseminated disease when administered intraperitoneally on days 3 and 5 post-infection.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> In 2020, mAb HENV-26 and mAb HENV-32, two naturally occurring human mAbs, were isolated from a donor immunised with a veterinary HeV protein subunit vaccine (Equivac; Zoetis, Rhodes, NSW, Australia) administered under compassionate use. These mAbs were shown to neutralise both HeV and NiV Bangladesh and Malaysia strains.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> In a NiV post-exposure prophylaxis model in ferrets, these mAbs also protected animals against disseminated disease when administered intraperitoneally on days 3 and 5 post-infection. Although their different epitope specificity would suggest that these mAbs could have synergistic properties if administered as a mAb cocktail, the mAbs were only tested separately in virus neutralisation assays and protective efficacy experiments. Furthermore, despite binding to NiV and HeV G proteins, the mAbs did not bind to G proteins from other henipaviruses such as Ghanaian bat henipavirus or Cedar henipavirus.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>
</p><p id="para200">The current engagement from academic, public, and biotechnology product developers is important for progression of the existing mAb pipeline. However, to further accelerate the development process and ensure that final products reach the target population, a clear strategy is required on the following four areas: scenario planning for product development and regulatory pathways in relation to disease epidemiology; further participation from industry, especially product developers with experience in the development of medical countermeasures against other pathogens, to lead and support henipavirus medical countermeasure development efforts; technical transfer and engagement of local manufacturers in endemic countries; and further progression of mAb development to clinical trials and potential licensure.</p></sec><sec id="cesec60"><title>Vaccines</title><p id="para210">A draft Nipah vaccine target product profile published by WHO<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> stipulates that a NiV vaccine be used for reactive immunisation (ie, active immunisation of at-risk individuals in the area of an ongoing outbreak) and &#8220;in conjunction with other control measures to curtail or end an outbreak&#8221;.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> In an outbreak scenario, key preferred characteristics of a NiV vaccine include an ability to elicit protective immunity rapidly (preferably within 2 weeks) after a single dose, acceptable safety profile, high efficacy (&gt;90%), thermostability (2&#8211;8&#176;C), and an ability to confer immunity and protection against Malaysia and Bangladesh strains of NiV.</p><p id="para220">Table 3 shows the current landscape of the henipavirus vaccine pipeline. There are more than 40 candidates in development with data available in the public domain; however, eight of these are intended primarily for veterinary use.<xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib77" ref-type="bibr">77</xref> Nearly half (n=19) of henipavirus vaccine candidates are based on viral vector platforms, 17 are protein subunits or virus-like particles formulated in various adjuvants, and two are based on mRNA technology. The main targets of henipavirus vaccines in development are the surface G glycoprotein or the fusion F protein. All listed vaccines are highly immunogenic and elicit henipavirus binding antibodies, neutralising antibodies, or both, with at least 15 candidates conferring various levels of protection against challenge with homologous or heterologous henipavirus strains in African green monkeys, Syrian golden hamsters, or ferrets (<xref rid="tbl3" ref-type="table">table 3</xref>
).<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Chronological overview of henipavirus vaccines in development, by platform</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>Vaccine regimen and administration route</bold></th><th align="left" colspan="1" rowspan="1"><bold>Animal models used</bold></th><th align="left" colspan="1" rowspan="1"><bold>Henipavirus challenge strain</bold></th><th align="left" colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1"><bold>Viral vectors</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant vaccinia viruses (modified vaccinia virus Ankara) expressing NiV-M or HeV F, G, or N</td><td align="left" colspan="1" rowspan="1">Single dose (intraperitoneal)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib56" ref-type="bibr">56</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Vaccinia virus vector (NYVAC) expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">2 doses, 1 month apart (subcutaneous)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib57" ref-type="bibr">57</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Canarypox vector (ALVAC) expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">2 doses, 14 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib58" ref-type="bibr">58</xref>, <xref rid="bib59" ref-type="bibr">59</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Venezuelan equine encephalitis virus expressing HeV or NiV-M G or F</td><td align="left" colspan="1" rowspan="1">3 doses on weeks 0, 5, and 18 (footpad inoculation)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib60" ref-type="bibr">60</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Replication-defective VSV-DG vector expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">Single dose (intranasal or intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib61" ref-type="bibr">61</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Newcastle disease virus vector expressing NiV-M F or G</td><td align="left" colspan="1" rowspan="1">2 doses, 4 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice, pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib62" ref-type="bibr">62</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Single-cycle replication VSV-DG vector expressing NiV-B G and/or F</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">Ferrets</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib63" ref-type="bibr">63</xref><xref rid="tbl3fn2" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Adeno-associated virus vector expressing NiV-M G</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M and HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib64" ref-type="bibr">64</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Measles virus vaccine vectors (HL and Ed strains) expressing NiV-M G</td><td align="left" colspan="1" rowspan="1">2 doses, 21 or 28 days apart (intraperitoneal [Syrian golden hamsters] or subcutaneous [African green monkeys])</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters, African green monkeys</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib65" ref-type="bibr">65</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Live-attenuated rVSV-ZEBOV-GP vector expressing NiV-M G, F, or N</td><td align="left" colspan="1" rowspan="1">Single dose (intraperitoneal)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib66" ref-type="bibr">66</xref><xref rid="tbl3fn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Single-cycle replication VSV-DG vector expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib67" ref-type="bibr">67</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Live-attenuated and beta-propiolactone-inactivated VSV or rabies virus vaccine vectors expressing codon-optimised HeV G</td><td align="left" colspan="1" rowspan="1">Single dose (live) or three doses (beta-propiolactone), on weeks 0, 2, and 3 (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib68" ref-type="bibr">68</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Live-attenuated rVSV-ZEBOV-GP vector expressing NiV-M G</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">African green monkeys</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib69" ref-type="bibr">69</xref><xref rid="tbl3fn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Live-attenuated rVSV-ZEBOV-GP vector expressing NiV-M G</td><td align="left" colspan="1" rowspan="1">Single dose (intraperitoneal)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib70" ref-type="bibr">70</xref><xref rid="tbl3fn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Canarypox vector (ALVAC) expressing HeV G or F</td><td align="left" colspan="1" rowspan="1">2 doses, 21 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters and ponies (horses)</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib71" ref-type="bibr">71</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Non-replicating VSV-DG vectors expressing NiV-M G and/or F</td><td align="left" colspan="1" rowspan="1">Single dose (intranasal or intracranial)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib72" ref-type="bibr">72</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Live-attenuated and beta-propiolactone-inactivated rabies virus vaccine vector expressing NiV-B G</td><td align="left" colspan="1" rowspan="1">Single dose (live) or 2 doses (beta-propiolactone), 28 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib73" ref-type="bibr">73</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Single-cycle replication VSV-DG vector expressing NiV-B G and/or F</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">African green monkeys</td><td align="left" colspan="1" rowspan="1">NiV-B</td><td align="left" colspan="1" rowspan="1"><xref rid="bib74" ref-type="bibr">74</xref><xref rid="tbl3fn2" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Chimpanzee adenovirus vector expressing NiV-B G</td><td align="left" colspan="1" rowspan="1">Single or two doses, 28 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M, NiV-B, and HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib75" ref-type="bibr">75</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Modified vaccinia virus Ankara expressing NiV-M sG or G</td><td align="left" colspan="1" rowspan="1">Single or 2 doses, 21 days apart (intraperitoneal or intramuscular)</td><td align="left" colspan="1" rowspan="1">IFNAR &#8722;/&#8722; mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib76" ref-type="bibr">76</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant rabies viruses Evelyn-Rokitnicki-Abelseth strain, rERAG<sub>333E</sub>expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">2 doses, 8 weeks apart (oral)</td><td align="left" colspan="1" rowspan="1">Mice and pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib77" ref-type="bibr">77</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Bovine herpes virus 4 or canarypox vectors (ALVAC) expressing NiV-M G or F</td><td align="left" colspan="1" rowspan="1">2 doses, 3 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib78" ref-type="bibr">78</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Protein subunits</bold><xref rid="tbl3fn4" ref-type="table-fn">&#167;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">sG<sub>NiV-M</sub> or sG<sub>HeV</sub> in CSIRO triple adjuvant (Montanide/QuilA/DEAE-dextran)</td><td align="left" colspan="1" rowspan="1">3 doses, 2 weeks apart (subcutaneous)</td><td align="left" colspan="1" rowspan="1">Cats</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib79" ref-type="bibr">79</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in CpG plus Alhydrogel adjuvant</td><td align="left" colspan="1" rowspan="1">2 doses, 21 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Cats</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib80" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Soluble trimeric forms of HeV and NiV-M F proteins (sF<sub>GCNt</sub>) in Sigma Adjuvant System adjuvant</td><td align="left" colspan="1" rowspan="1">4 doses, each 30 days apart (intraperitoneal or subcutaneous)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib81" ref-type="bibr">81</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in CpG and Alhydrogel adjuvant</td><td align="left" colspan="1" rowspan="1">2 doses, 21 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">African green monkeys</td><td align="left" colspan="1" rowspan="1">NiV M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib82" ref-type="bibr">82</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in Alhydrogel and CpG adjuvant</td><td align="left" colspan="1" rowspan="1">2 doses, 20 days apart (subcutaneous)</td><td align="left" colspan="1" rowspan="1">Ferrets</td><td align="left" colspan="1" rowspan="1">NiV B</td><td align="left" colspan="1" rowspan="1"><xref rid="bib83" ref-type="bibr">83</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in Alhydrogel with or without CpG adjuvant</td><td align="left" colspan="1" rowspan="1">2 doses, 21 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">African green monkeys</td><td align="left" colspan="1" rowspan="1">HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib84" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein (produced in 293 or Chinese hamster ovary cells) in a proprietary adjuvant (Zoetis, Inc)</td><td align="left" colspan="1" rowspan="1">2&#8211;5 doses, weeks 0 and 3, then at 6 months and then yearly (intramuscular)</td><td align="left" colspan="1" rowspan="1">Horses<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in a proprietary adjuvant (Zoetis, Inc)</td><td align="left" colspan="1" rowspan="1">2 doses, 21 days apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">NiV-M and HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib87" ref-type="bibr">87</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein in alhydrogel + CpG adjuvant</td><td align="left" colspan="1" rowspan="1">2 doses, 20 days apart (subcutaneous)</td><td align="left" colspan="1" rowspan="1">Ferrets</td><td align="left" colspan="1" rowspan="1">HeV</td><td align="left" colspan="1" rowspan="1"><xref rid="bib88" ref-type="bibr">88</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Molecular clamp-stabilised F protein (mcsF)</td><td align="left" colspan="1" rowspan="1">2 doses, 3 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Pigs<xref rid="tbl3fn1" ref-type="table-fn">*</xref></td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib5" ref-type="bibr">5</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Multiple pre-fusion-stabilised F and oligomeric G proteins derived from NiV-M and formulated in aluminum hydroxide</td><td align="left" colspan="1" rowspan="1">2 doses, 3 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib89" ref-type="bibr">89</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Monovalent, bivalent, and tetravalent Fc-linked G proteins from NiV-M, HeV, GhV, and MojV formulated in CpG and Alhydrogel</td><td align="left" colspan="1" rowspan="1">2 doses, 3 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib90" ref-type="bibr">90</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Recombinant soluble HeV G glycoprotein, produced in HEK-293 cells, formulated in Alhydrogel</td><td align="left" colspan="1" rowspan="1">Single dose or 2 doses, 4 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">African green monkeys</td><td align="left" colspan="1" rowspan="1">HeV (Brisbane) and NiV B</td><td align="left" colspan="1" rowspan="1"><xref rid="bib91" ref-type="bibr">91</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Virus-like particles</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-like particles containing NiV-M M, G, and F<xref rid="tbl3fn5" ref-type="table-fn">&#182;</xref></td><td align="left" colspan="1" rowspan="1">3 doses on days 0, 15, and 29 (subcutaneous)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib92" ref-type="bibr">92</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-like particles containing NiV-M M, F, and G, formulated in various adjuvants (alum, monophosphoryl lipid A, and CpG)<xref rid="tbl3fn5" ref-type="table-fn">&#182;</xref></td><td align="left" colspan="1" rowspan="1">Single dose or 3 doses on days 0, 21, and 42 (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib93" ref-type="bibr">93</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-like particles containing NiV-M M and F or G in Sigma Adjuvant System</td><td align="left" colspan="1" rowspan="1">3 doses on weeks 0, 3, and 5 (intramuscular)</td><td align="left" colspan="1" rowspan="1">Rabbits</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib94" ref-type="bibr">94</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-like particles containing NiV-M F and G and HeV M</td><td align="left" colspan="1" rowspan="1">3 doses on weeks 0, 3, and 6 (intraperitoneal)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib95" ref-type="bibr">95</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Cellular debris</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Pellets and supernatants from sF9 cells expressing recombinant NiV-M F and G proteins in a baculovirus system</td><td align="left" colspan="1" rowspan="1">2 doses, 3 weeks apart (intramuscular and intraperitoneal)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib96" ref-type="bibr">96</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>DNA</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Plasmids encoding codon-optimised NiV-M F and/or G</td><td align="left" colspan="1" rowspan="1">2 doses, 4 weeks apart (intramuscular)</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1"><xref rid="bib97" ref-type="bibr">97</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Plasmids encoding NiV-M F and/or G</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular) followed by electroporation</td><td align="left" colspan="1" rowspan="1">Mice</td><td align="left" colspan="1" rowspan="1">NiV-M pseudovirus</td><td align="left" colspan="1" rowspan="1"><xref rid="bib98" ref-type="bibr">98</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>mRNA</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">HeV G codon-optimised mRNA in liquid nanoparticles</td><td align="left" colspan="1" rowspan="1">Single dose (intramuscular)</td><td align="left" colspan="1" rowspan="1">Syrian golden hamsters</td><td align="left" colspan="1" rowspan="1">NiV-M</td><td align="left" colspan="1" rowspan="1"><xref rid="bib99" ref-type="bibr">99</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-1215, mRNA encoding NiV-M F and G in liquid nanoparticles</td><td align="left" colspan="1" rowspan="1">To be determined</td><td align="left" colspan="1" rowspan="1">Undisclosed preclinical development</td><td align="left" colspan="1" rowspan="1">To be determined</td><td align="left" colspan="1" rowspan="1"><xref rid="bib100" ref-type="bibr">100</xref></td></tr></tbody></table><table-wrap-foot><fn><p>GhV=Ghanaian bat henipavirus. GP=glycoprotein. HeV=Hendra virus. MojV=Mojiang henipavirus. NiV=Nipah virus. NiV-B=Nipah virus Bangladesh. NiV-M=Nipah virus Malaysia. rVSV=recombinant vesicular stomatitis virus. VSV=vesicular stomatitis virus. ZEBOV=Zaire Ebola virus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn1"><label>*</label><p id="cenpara20">These vaccines are intended primarily for veterinary use.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn2"><label>&#8224;</label><p id="cenpara30">The single-cycle replication VSV-DG vector expressing NiV-B G and/or F is identical in these studies.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn3"><label>&#8225;</label><p id="cenpara40">The live-attenuated rVSV-ZEBOV-GP vector expressing NiV-M G is identical in these studies.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn4"><label>&#167;</label><p id="cenpara50">The soluble HeV G protein is identical in all studies using different adjuvant formulations.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn5"><label>&#182;</label><p id="cenpara60">The virus-like particles are identical in these studies using different formulations.</p></fn></table-wrap-foot></table-wrap></p><p id="para230">The recombinant, soluble HeV G glycoprotein candidate is the only vaccine candidate that has progressed to phase 1 clinical trials.<xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib101" ref-type="bibr">101</xref> This candidate builds on existing knowledge gained from using the same soluble protein in several pre-clinical and veterinary studies,<xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib85" ref-type="bibr">85</xref> including pivotal data used to develop the Equivac HeV vaccine approved for veterinary use in horses.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> In addition to good manufacturing practices and good clinical practices required to develop the soluble HeV G product for human use, a key difference between the vaccine intended for humans and its previous versions is the adjuvant formulation in Alhydrogel (Croda, USA) at a 1:10 ratio.<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref>
</p><p id="para240">It is too early to ascertain whether any of these candidate vaccines will achieve licensure and meet the preferred product characteristics described in the draft WHO target product profile for a NiV vaccine.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> The low temperature requirement could create challenges for some vaccine candidates; however, this problem is currently being addressed with COVID-19 vaccines and is not necessarily a barrier, as even a small amount of ultracold chain capacity can be established rapidly during vaccine deployment in response to an outbreak.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> The single-dose vaccine regimen and cross-protection characteristics as described in the WHO target product profile might be possible to achieve. For example, a single dose of the ChAdOx-NiV Bangladesh vaccine candidate cross-protects Syrian golden hamsters against challenge with HeV and the NiV-Malaysia strain.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>
</p><p id="para250">The global effort to develop COVID-19 vaccines might pose a substantial risk to henipavirus vaccine development capacity, including delays in animal studies and reduced manufacturing capacity and funding. However, COVID-19 vaccine development has also accelerated many of the vaccine platform technologies that could be applied to henipavirus vaccine development and rapid response. Among these, the henipavirus mRNA vaccine candidates are likely to benefit from the experience in COVID vaccine development, scale-up manufacturing, regulatory approval, and deployment.</p></sec></sec><sec id="cesec70"><title>Projected costs of henipavirus medical countermeasures in a post-COVID-19 era</title><p id="para260">The current henipavirus medical countermeasure pre-clinical and clinical landscape includes nine small molecules, four mAbs, and 15 vaccine candidates. Included candidates are those with clinical data in humans or proof-of-concept data in ferrets, Syrian golden hamsters, or African green monkeys. This list of candidates excludes those with only exploratory in-vitro data, or pre-clinical data without a known henipavirus challenge study. The development pipeline is heavily shifted towards vaccines because these are potentially the most effective public health intervention. The main funders of currently active henipavirus vaccine development projects are listed in <xref rid="sec1" ref-type="sec">appendix p 3</xref>. In addition to these, the National Institute of Allergy and Infectious Diseases has supported and continues to fund the development of henipavirus mAbs and other medical countermeasures.<xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref>, <xref rid="bib105" ref-type="bibr">105</xref> Furthermore, as part of its new strategic priorities, the Coalition for Epidemic Preparedness Innovations (CEPI) aims to support the development of a fully licensed vaccine or prophylactic mAb against Nipah by 2027.<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref>
</p><p id="para270">Despite this progress, the development of vaccines and treatments against infectious diseases is a lengthy, costly, and risky process. The development of medical countermeasures against COVID-19 has proved that at least the speed of product development can be partially overcome with broad mobilisation of public and philanthropic funding, and engagement of scientists, policymakers, epidemiologists, public and private vaccine developers, manufacturers, and regulators involved in emergency use processes. However, this advanced speed comes with additional costs due to a greater number of projects entering the pipeline, and at-risk costs needed for large-scale manufacturing of various leading products in parallel before conclusion of the clinical testing.<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> COVID-19 medical countermeasure investments will probably increase the speed of product development and the number of medical countermeasure platform technologies against other pathogens, including those against henipavirus. <xref rid="tbl4" ref-type="table">Table 4</xref>
estimates the costs of potential henipavirus medical countermeasures in a post-COVID-19 era. Vaccines and small molecule regimens will continue to be more affordable per person than mAbs. However, vaccine impact at large, including vaccine effectiveness and cost-effectiveness of potential medical countermeasures, will need to be determined in a post-authorisation and post-licensure era.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Projected costs of henipavirus medical countermeasures</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>Reference price</bold><xref rid="tbl4fn1" ref-type="table-fn">*</xref><bold>(US$)</bold></th><th align="left" colspan="1" rowspan="1"><bold>Reference cost unit</bold></th><th align="left" colspan="1" rowspan="1"><bold>Potential dose regimen</bold></th><th align="left" colspan="1" rowspan="1"><bold>Estimated cost of regimen per person (US$)</bold></th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1"><bold>Small molecules or therapeutics</bold><xref rid="tbl4fn2" ref-type="table-fn">&#8224;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Remdesivir</td><td align="left" colspan="1" rowspan="1">53 per vial (Cipla Limited, Mumbai, India)</td><td align="left" colspan="1" rowspan="1">100 &#956;g vial</td><td align="left" colspan="1" rowspan="1">Ebola regimen; intravenous: 200 mg (loading dose) + 10 mg for 10 days</td><td align="left" colspan="1" rowspan="1">$640</td></tr><tr><td align="left" colspan="1" rowspan="1">Favipiravir</td><td align="left" colspan="1" rowspan="1">&lt;0&#183;50 per tablet (Mylan Laboratories Limited, Hyderabad, India)</td><td align="left" colspan="1" rowspan="1">200 mg tablet</td><td align="left" colspan="1" rowspan="1">Influenza regimen: oral: 1800 mg twice daily (loading dose) + 800 mg twice daily for 14 days</td><td align="left" colspan="1" rowspan="1">$31</td></tr><tr><td align="left" colspan="1" rowspan="1">Ribavirin</td><td align="left" colspan="1" rowspan="1">&lt;1 per tablet</td><td align="left" colspan="1" rowspan="1">200 mg tablet (oral) or 10 mg vial (intravenous)</td><td align="left" colspan="1" rowspan="1">Chong et al<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Nipah regimen; oral: 2 g (loading dose) + 1 g for 10 daysIntravenous: 30 mg/kg (loading dose) + 16 mg/kg every 6 h for 4 days + 8 mg/kg every 8 h for 3 days</td><td align="left" colspan="1" rowspan="1">$20&#8211;60 (oral); $14&#8211;26 (intravenous)</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Monoclonal antibodies</bold><xref rid="tbl4fn3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Monoclonal antibodies produced in mammalian cell lines</td><td align="left" colspan="1" rowspan="1">1250&#8211;2100 per vial</td><td align="left" colspan="1" rowspan="1">700 mg&#8211;2&#183;4 g per dose</td><td align="left" colspan="1" rowspan="1">COVID-19-like regimens; single intravenous infusion</td><td align="left" colspan="1" rowspan="1">$1250&#8211;2100 (intravenous) <xref rid="bib108" ref-type="bibr">108</xref>, <xref rid="bib109" ref-type="bibr">109</xref>, <xref rid="bib110" ref-type="bibr">110</xref></td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>Vaccines</bold><xref rid="tbl4fn4" ref-type="table-fn">&#167;</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Viral vectors, protein subunits in adjuvant, and mRNA in liquid nanoparticles</td><td align="left" colspan="1" rowspan="1">4&#8211;37 per dose</td><td align="left" colspan="1" rowspan="1">Variable concentration per dose</td><td align="left" colspan="1" rowspan="1">Single or two-dose regimen</td><td align="left" colspan="1" rowspan="1">$8&#8211;74<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tbl4fn1"><label>*</label><p id="cenpara70">Prices based on publicly available information of generic product costs, or products developed using similar platforms.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fn2"><label>&#8224;</label><p id="cenpara80">Costs exclude expenses related to hospital care infrastructure and administration, supportive therapy, and disposables, etc.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fn3"><label>&#8225;</label><p id="cenpara90">Reference data for monoclonal antibodies are based on data available in the public domain for bamlanimivab (Eli Lilly, Indianapolis, IN, USA) and casirivimab plus imdevimab (REGN-COV2 antibody cocktail [Regeneron, Tarrytown, NY, USA]).<xref rid="bib90" ref-type="bibr">90</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>, <xref rid="bib95" ref-type="bibr">95</xref>, <xref rid="bib96" ref-type="bibr">96</xref>, <xref rid="bib97" ref-type="bibr">97</xref>, <xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref></p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fn4"><label>&#167;</label><p id="cenpara100">Costs exclude expenses related to vaccine delivery, transport, refrigeration, and administration.</p></fn></table-wrap-foot></table-wrap></p><sec id="cesec80"><title>Small molecules</title><p id="para280">For small molecules, we project costs ranging from US$14 to $600 per person per regimen (<xref rid="tbl4" ref-type="table">table 4</xref>). Advantages are associated with repurposing commercially available products for new indications, including the cost benefits of limited additional investments needed to ramp up supply, or in the cases of remdesivir and favipiravir, the leverage scale from demand generated by the current COVID-19 indication. Furthermore, commercialised drugs are likely to have a reliable supply chain of generic versions at substantially reduced costs, with the potential for a good investment case for pre-exposure or post-exposure prophylaxis for high-risk populations in affected areas. An example of a prophylaxis campaign during an outbreak would be the use of oseltamivir (Tamiflu; F Hoffmann-La Roche AG, Basel, Switzerland) during the 2009 influenza A (H1N1) pandemic.<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref> For henipavirus outbreaks, however, further supportive evidence in animal models and clinical trials will be needed in support of a mass prophylaxis concept. The route of administration will be especially relevant in an outbreak scenario&#8212;for example, daily intravenous administration of remdesivir would be limited by cost, infrastructure, and the need for hospital stays.</p></sec><sec id="cesec90"><title>mAbs</title><p id="para290">For mAbs, we project costs of more than $1000 per person per regimen (<xref rid="tbl4" ref-type="table">table 4</xref>). Further funding will be required to advance henipavirus mAb programmes into early-stage and late-stage clinical development. Delivery of mAbs, especially via intravenous infusion, requires capacity and infrastructure, which could prove challenging in some outbreak settings. Subcutaneous administration of mAbs against COVID-19 is being tested and submitted for licensure.<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref> If successful, this concept will fundamentally improve access to mAb treaments. Casirivimab and imdevimab (Regeneron [Tarrytown, NY, USA]) and bamlanivimab (Eli Lily [Indianapolis, IN, USA) COVID-19 mAbs have rapidly completed phase 1 trials and received emergency use listings as treatment against mild and moderate COVID-19,<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref> setting the precedent for future emulation in a henipavirus outbreak. However, further data are needed regarding the added benefit to children and adolescents, and the prophylactic indication for mAbs.<xref rid="bib114" ref-type="bibr">114</xref>, <xref rid="bib115" ref-type="bibr">115</xref>
</p></sec><sec id="cesec100"><title>Vaccines</title><p id="para300">The cost of henipavirus vaccines in an epidemic or pandemic setting remains unclear; however, experience from COVID-19 vaccines using similar platforms suggests the price of vaccines could range between $4 per dose for viral vector vaccines to $37 per dose for mRNA vaccines.<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref> These figures do not include delivery costs, which could add substantially to the immunisation costs depending on vaccine logistics, infrastructure, and regimens.<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref> The cost per dose of a henipavirus vaccine in the scenario of a small number of outbreaks and a modest stockpile could also be higher as a result of the lower market potential. Although this price estimate is a wide range, vaccines might still be reasonably priced by comparison with other medical countermeasures such as mAbs. Public funding for research and development and advance purchase agreements could keep the cost affordable.</p></sec><sec id="cesec110"><title>Further investments in diagnostics and virological surveillance</title><p id="para310">Laboratory-based diagnostic testing, contact tracing, and proactive quarantine and treatment of suspected cases, often collectively referred to as &#8220;test, track/trace, and treat&#8221; strategies, are indicated at the onset of an outbreak and can quickly isolate and treat patients to halt further spread of henipaviruses.<xref rid="bib117" ref-type="bibr">117</xref>, <xref rid="bib118" ref-type="bibr">118</xref> Currently, however, no near-patient or point-of-care tests are currently used for Nipah or Hendra viruses, which is likely to be a major limitation for the development of other medical countermeasures. Incentivisation is therefore needed to commercialise diagnostic assays and to adapt them for early detection of henipavirus encephalitis in suspected epidemic or pandemic settings.</p><p id="para320">Although numerous in-house serological methods (ELISA) and nucleic acid amplification techniques (PCR) for NiV detection exist globally,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> harmonisation of validation methods, standards, and reagents to facilitate development of commercial PCR kits is needed. A reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay for the <italic toggle="yes">NiV N</italic> gene has recently been developed and is significantly more sensitive than RT-PCR, demonstrating potential for a quicker and simple rapid diagnostic test for use in outbreak settings.<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref> Key barriers to the development of henipavirus diagnostic tests include: the scarcity of widely available sera from henipavirus survivors, which might be necessary to accelerate the evaluation, validation, and licensure of serologic diagnostics for human use; and the BSL4 laboratory requirements for diagnostics dependent on virus isolation and wild-type virus neutralisation assays.</p><p id="para330">Notably, all experimental knowledge on Nipah virus acquired over the past two decades is derived from only two virus strains (199902916 Malaysia and 200401066 Bangladesh).<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref> Investments in surveillance, virus isolation, and sequencing can further our understanding of the impact of Nipah virus strain variation on medical countermeasure efficacy.</p></sec></sec><sec id="cesec120"><title>Regulatory considerations</title><p id="para340">Modelling to evaluate the feasibility of conducting a phase 3 NiV vaccine trial in Bangladesh suggests that under the present low incidence scenario, traditional randomised, controlled efficacy trials are not feasible.<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref> Alternative licensure pathways in lieu of a traditional phase 3 vaccine efficacy trial, as described in the following paragraphs, should be considered.</p><sec id="cesec130"><title>Regulatory pathways</title><p id="para350">Various pathways exist for the licensure of new medical countermeasures or medical countermeasures for life-threatening diseases (<xref rid="tbl5" ref-type="table">table 5</xref>
). These options include accelerated approval (by the Food and Drugs Administration [FDA]<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> or the animal efficacy rule<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> in the USA), and conditional approval or exceptional circumstances in the European Union (EU).<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> These regulatory pathways might be suitable for the licensure of medical countermeasures against viruses that have unpredictable outbreak patterns and are not conducive to phase 3 human clinical efficacy trials.<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref> However, NiV outbreaks are very unlikely to occur where the US FDA or the European Medicines Agency (EMA) have jurisdiction. Therefore, further development of the regulatory procedures in potentially affected countries is paramount. In the absence of specific regulatory mechanisms in affected countries, this article will reference the US FDA and the EMA regulatory procedures. The US accelerated approval pathway allows for surrogate or clinical intermediate endpoints and is used for therapies for serious conditions &#8220;as soon as it can be concluded that [their] benefits justify their risks&#8221;.<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref> For henipaviruses, an example of a surrogate endpoint could be a protective titre of virus-neutralising antibodies. Accelerated approval would only be granted with a post-marketing commitment to demonstrate efficacy in a well-controlled clinical trial at the time of an outbreak. Given the epidemiology of NiV, timely fulfilment of this commitment would be problematic.<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Potential regulatory pathways to pursue henipavirus vaccine authorisation</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"><bold>Data package could include</bold></th><th align="left" colspan="1" rowspan="1"><bold>Examples of approved vaccines for other indications</bold></th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1"><bold>Current scenario: R</bold><sub>o</sub><bold>&lt;1</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Accelerated approval (US FDA),<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> conditional marketing authorisation or exceptional circumstances approval (EMA),<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> or similar mechanisms</td><td align="left" colspan="1" rowspan="1">Phase 1 data, phase 2 data<xref rid="tbl5fn1" ref-type="table-fn">*</xref>, phase 3 trial feasibility assessment (results from mathematical modelling), assay validation data, surrogate endpoint or correlates of protection data, passive transfer or adoptive transfer studies, bridging data for licensure, and post-approval confirmatory studies to demonstrate clinical benefit</td><td align="left" colspan="1" rowspan="1">Approvals based on surrogate endpoints;<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref> conditional marketing authorisation for Ervebo (recombinant vesicular stomatitis virus&#8211;Zaire Ebola virus)<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Animal rule (US FDA)<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> and exceptional circumstances (EMA)<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref></td><td align="left" colspan="1" rowspan="1">Natural history study data and challenge data, additional requirements requested by national regulatory authorities for licensure, and post-approval confirmatory studies to demonstrate clinical benefit (if possible to conduct)</td><td align="left" colspan="1" rowspan="1">Approvals based on the animal rule;<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref> exceptional circumstances: Zabdeno (Ad26.ZEBOV [adenovirus type 26 vector-based vaccine, expressing a Zaire Ebola virus glycoprotein])<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref> and Mvabea (MVA-BN-Filo [modified vaccinia Ankara vector-based vaccine, encoding glycoproteins from the Zaire Ebola virus])<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref></td></tr><tr><td align="left" colspan="1" rowspan="1">Other, depending on specific national regulatory authority legislation. See Directorate General of Drug Administration, (Bangladesh)<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref> and the Central Drugs Standard Control Organization (India)<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref> as examples</td><td align="left" colspan="1" rowspan="1">To be defined by each national regulatory authority</td><td align="left" colspan="1" rowspan="1">Vary by different national regulatory authority</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Alert phase: R<sub>o</sub> ~1</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Rapid response: potential shift to PHEIC and pandemic scenarios</td><td align="left" colspan="1" rowspan="1">..</td><td align="left" colspan="1" rowspan="1">..</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Higher incidence scenarios: R</bold><sub>o</sub><bold>&gt;1</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Accelerated approval (US FDA),<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> conditional marketing authorisation (EMA),<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> national regulatory authority emergency use authorisation, WHO EUL, <xref rid="bib132" ref-type="bibr">132</xref>, <xref rid="bib133" ref-type="bibr">133</xref> and other</td><td align="left" colspan="1" rowspan="1">Phase 1 data, phase 2 data, and assay validation data<xref rid="tbl5fn2" ref-type="table-fn">&#8224;</xref></td><td align="left" colspan="1" rowspan="1">Ebola vaccines: Ervebo<xref rid="bib125" ref-type="bibr">125</xref>, <xref rid="bib134" ref-type="bibr">134</xref></td></tr></tbody></table><table-wrap-foot><fn><p>EMA=European Medicines Agency. EUL=emergency use listing. PHEIC=public health emergency of international concern. US FDA=US Food and Drug Administration.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn1"><label>*</label><p id="cenpara110">Phase 2 clinical trial material can become so-called &#8220;outbreak-ready&#8221; for an investigational stockpile.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fn2"><label>&#8224;</label><p id="cenpara120">Investigational stockpile deployed.</p></fn></table-wrap-foot></table-wrap></p><p id="para360">The animal efficacy rule (US FDA) entails using animal efficacy data instead of human clinical data.<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> To support licensure through this route, the efficacy of a medical countermeasure can be demonstrated using a disease endpoint in a relevant animal model that enables the selection of an effective dose and regimen in humans. The animal efficacy rule approval pathway is only available in a situation where licensure through the traditional or accelerated approval pathway is not feasible. Generating the data required for approval via this pathway is challenging. So far, there has been only one precedent for a vaccine approval using the animal rule (BioThrax [Emergent BioSolutions, Rockville, MD, USA<bold>]</bold> for post-exposure prophylaxis following suspected or confirmed anthrax exposure). The process and data requirements were substantial, taking at least 5 years from conception of the regulatory pathway to approval.<xref rid="bib137" ref-type="bibr">137</xref>, <xref rid="bib138" ref-type="bibr">138</xref> To gain approval via the animal rule, data must be generated to demonstrate a reasonably good understanding of the pathophysiology of the disease in a chosen animal model, and preferably in more than one animal species.<xref rid="bib139" ref-type="bibr"><sup>139</sup></xref> Well-designed natural history studies must be done, with solid evidence that the models can recapitulate key aspects of human disease. There have been relatively few human cases of henipavirus encephalitis to enable description of the full human clinical and pathological basis of the disease; therefore, animal disease comparisons might not reveal all features of human disease. Finally, whether or not the available strains of henipavirus encephalitis (as well as the challenge dose and method of administration) used in the animal challenge studies are epidemiologically relevant remains unclear. Hence, using the the animal rule to obtain approval for a vaccine against NiV may be challenging.</p><p id="para370">In the European Union (EU), the conditional marketing authorisation<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> has some similarities to the US accelerated approval procedure. The following criteria must be met: the benefit&#8211;risk balance must be positive; the product must fulfil an unmet medical need; the benefit of making the product immediately available must be greater than the risk of additional data still being required; and comprehensive data post-authorisation must be provided in a timely manner. As is the case for the accelerated approval pathway, fulfilment of the latter is problematic given the epidemiology of NiV.</p><p id="para380">EU legislation also allows marketing authorisation to be granted in the absence of comprehensive data under exceptional circumstances.<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref> Unlike conditional marketing authorisation, where marketing approval is granted in the likelihood that the sponsor will provide such data post-approval within an agreed timeframe, the EMA can grant authorisation under exceptional circumstances when comprehensive data cannot be obtained even after authorisation. For example, approval under exceptional circumstances was granted in July, 2020, for Zabdeno<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref> and Mvabea<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref> (both Janssen-Cilag International NV, Beerse, Belgium) against Ebola virus in individuals 1 year of age or older. The fact that Zabdebo and Mvabea received approval under exceptional circumstances in the EU but is yet to be approved in the USA implies that the EU exceptional circumstances regulatory route may be less challenging than the animal rule in the USA.</p><p id="para390">Early discussions with the US FDA and EMA are critical to establish specific data requirements and map the most appropriate route to approval for the developer. Importantly, the aforementioned US and EU regulatory routes are defined within specific legislation and require robust technical capabilities, especially with regard to the review and acceptance of animal efficacy data. Further work will be needed to evaluate the extent to which existing legislation in henipavirus-affected countries provides an appropriate level of flexibility to allow the use of animal efficacy data as the basis for regulatory approval. If such mechanisms are not available, the development of similar legislation should be considered by those countries where future henipavirus outbreaks could occur.</p></sec><sec id="cesec140"><title>Pre-licensure mechanisms: emergency use of vaccines</title><p id="para400">National regulatory authorities might consider the authorisation of vaccines in their jurisdiction by allowing the use of an investigational product in emergency situations <italic toggle="yes">(R</italic>
<sub>0</sub>&gt;1<italic toggle="yes">),</italic> such as in the event of a henipavirus pandemic, or if a public health emergency of international concern (PHEIC) is declared by WHO. Preparedness efforts can speed up the time from the declaration of a PHEIC to the licensure of vaccines for emergency use. The WHO emergency use listing procedure<xref rid="bib132" ref-type="bibr">132</xref>, <xref rid="bib133" ref-type="bibr">133</xref>, <xref rid="bib140" ref-type="bibr">140</xref> has enabled rapid deployment of COVID-19 vaccines to a broad range of countries.</p><p id="para410">All countries with potential for a henipavirus outbreak must have emergency legislation to enable the rapid deployment of vaccines in the event an emergency use listing is granted by WHO. Since there might be a delay between the emergence of a henipavirus outbreak and declaration of a PHEIC, national regulatory authorities should also have legislation to enable the deployment of vaccines under their own emergency measures.</p><p id="para420">Data packages for vaccine candidates with some clinical data could be formally submitted to regulators in those countries where future outbreaks might occur and an authorisation could be requested based on existing clinical and non-clinical data, supplemented by data from the vaccine platform technology. These data could undergo a regulatory assessment based on anticipating the local benefit&#8211;risk in the country of deployment in the event of an outbreak. This would allow research to continue and additional data to be generated to support licensure. Such a licensed vaccine could be rapidly deployed in an attempt to control the emerging outbreak. Effectiveness and pharmacovigilance data could be collected in the real-world setting to confirm vaccine efficacy and safety. Although there is no current regulatory mechanism to support this, we advocate for an open debate on the feasibility of this approach. Case studies from the deployment of COVID-19 vaccines licensed in China, India, and Russia before the availability of phase 3 efficacy data, as well as learnings from undertaking clinical vaccine trials during the 2014&#8211;16 west African Ebola outbreak, could contribute to the framing of innovative regulatory frameworks in response to future pandemics.</p><p id="para430">A minimal dataset will be reviewed by regulatory authorities to enable rapid access and deployment of a vaccine during an emergency, irrespective of the regulatory mechanism used. As such, the ultimate objective of early deployment should be to continue to generate and collect the appropriate level of data to confirm effectiveness and achieve full licensure of the vaccine.</p><p id="para440">In the event that vaccines against NiV, HeV, or both do achieve licensure, it will also be important to advocate for implementation of accelerated regulatory approaches to enable the use of so-called core dossiers based on the pre-pandemic strains<xref rid="bib141" ref-type="bibr">141</xref>, <xref rid="bib142" ref-type="bibr">142</xref>, <xref rid="bib143" ref-type="bibr">143</xref>, <xref rid="bib144" ref-type="bibr">144</xref> and manufacturing technology platform experience to rapidly enable a strain change in the event that the henipavirus outbreak contains mutations that make the licensed vaccines less efficacious due to insufficient cross-reactivity.</p></sec></sec><sec id="cesec150"><title>Ensuring equitable access</title><p id="para450">Crucially, affected populations must be able to access medical countermeasures irrespective of cost. Four countries (Bangladesh, India, Malaysia, and the Philippines) historically affected by henipaviruses are low-income or middle-income countries<xref rid="bib145" ref-type="bibr"><sup>145</sup></xref> whereas two (Australia and Singapore) are high-income countries. Australia is the first country with a HeV vaccine and a documented, in-country stockpile of a henipavirus mAb, m102&#183;4, which has been administered for compassionate use.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> With scientific expertise in HeV, BSL4 capacity, and a renowned medical countermeasure consortia,<xref rid="bib146" ref-type="bibr"><sup>146</sup></xref> Australia could be a leading stakeholder in ensuring access through large-scale manufacturing and technology transfer of mAbs in the western Pacific region. In countries like Bangladesh, where Nipah outbreaks have predominantly affected poor populations in rural areas and health-care expenditures are generally out-of-pocket expenses,<xref rid="bib147" ref-type="bibr"><sup>147</sup></xref> central and local governments can prepare for future outbreaks by adapting strategies to reduce out-of-pocket expenses<xref rid="bib148" ref-type="bibr"><sup>148</sup></xref> or by devising mechanisms to share the costs of medical countermeasure procurement, deployment, and delivery, avoiding any undue delays to populations in need, regardless of their ability to pay for treatment.</p><p id="para460">Strategies to reduce the cost of medical countermeasure production while increasing the number of market players would help to increase access to medical countermeasures for low-income and middle-income countries; however, this approach is challenging in the face of a somewhat small henipavirus medical countermeasure portfolio. There might be little financial incentive perceived by multinational pharmaceutical companies, which have the most competitive resources and manufacturing capacity to invest in medical countermeasures.<xref rid="bib149" ref-type="bibr">149</xref>, <xref rid="bib150" ref-type="bibr">150</xref> Several initiatives have been set up to address this gap&#8212;for example, CEPI has invested more than $100 million in the pre-clinical and clinical development of four NiV vaccine candidates, including a protein subunit vaccine,<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> a measles vector-based vaccine,<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> a vesicular stomatitis virus vector-based vaccine,<xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref> and a chimpanzee adenovirus vector vaccine.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> NiV investigational vaccine stockpiles and other medical countermeasures, together with operations for intervention in the field, should be in place before a major epidemic or pandemic.<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref> However, more financial investment and continued participation from governments and the pharmaceutical private sector will be required to achieve this goal. The public, philanthropic, and private funding of active henipavirus vaccine development projects (<xref rid="sec1" ref-type="sec">appendix p 3</xref>) could help to decouple the price of the product from the cost of research and development, making it potentially more affordable. Efforts to increase supply and local manufacturing are also needed to potentially reduce prices and spur innovation. Funders must therefore include low-income and middle-income countries and strengthen their capacities in the crucial stages of vaccine development such as manufacturing, for example by establishing mechanisms to transfer technology and know-how to emerging developers in low-income and middle-income countries.<xref rid="bib152" ref-type="bibr"><sup>152</sup></xref>
</p><p id="para470">Compared with vaccines, small molecules and antivirals are easier to generically produce. The COVID-19 pandemic has demonstrated that in some cases, prices can be set fairly low by overcoming intellectual property issues.<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref> Therefore, both upstream and downstream strategies that address such issues across all the medical countermeasures will be vital for accessibility.</p><p id="para480">Funding agencies, sponsors, and manufacturers of henipavirus medical countermeasures must share the responsibility of understanding regulatory requirements to apply for emergency use or relevant authorisation of henipavirus medical countermeasures in affected countries. Poor knowledge of country-specific regulatory pathways can potentially create authorisation delays and an access roadblock for affected countries. Communication between product developers and the appropriate national regulatory authorities is essential to obtain clarity and guidance on local clinical trial requirements, regulatory legislation, and import requirements. Regulatory pathways and national regulatory authority capabilities vary between henipavirus-affected countries; thus, early engagement with regulators, preferably as soon as a target product profile is conceived with defined target populations, is essential to identify country-specific considerations.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>
</p><p id="para490">Coordination and cooperation among all stakeholders is crucial to ensure equitable access to henipavirus medical countermeasures. Although the price of the various measures could be reduced, supply might still be low in the case of a large outbreak or pandemic, as is the case with COVID-19.<xref rid="bib154" ref-type="bibr"><sup>154</sup></xref> Improved mechanisms to facilitate mobilisation, coordination, and cooperation across all the stakeholders are required.</p></sec><sec id="cesec160"><title>Conclusion</title><p id="para500">In this Review we have presented an overview of several medical countermeasures under development that have the potential to control henipavirus outbreaks. The pipeline of such measures is diverse (and mostly in the pre-clinical stage), with vaccines leading both in the number of candidates and the lowest anticipated cost per person per regimen. Investment in a combined portfolio of several medical countermeasures, including surveillance systems, should be part of a coordinated, multilateral strategy for epidemic and pandemic preparedness given the unpredictability of outbreaks and the high case&#8211;fatality rate. Given such risk, ethical considerations must feature prominently when planning clinical trials and establishing the trial design before the outbreak. Active exchange of data between developers of human and animal medical countermeasures should be encouraged. Regulatory agencies across different nations will require convincing data packages to approve the start of human clinical testing. Animal efficacy data collected in well-designed, high-quality studies could enable the start of these clinical studies and the collection of further data to support licensure via non-traditional regulatory pathways. For these efforts to be effective, multilateralism will be necessary. Multilateral strategies should be based on scenario planning and include an outbreak response plan that clearly delineates responsibilities for the coordinated, sequential deployment of medical countermeasures in the event of a henipavirus outbreak. The current COVID-19 pandemic opens a timely and unique opportunity to implement lessons learned from SARS-CoV-2 and apply them to preparedness efforts against henipaviruses and other pathogens of pandemic potential.</p></sec><sec sec-type="COI-statement"><title>Declaration of interests</title><p id="para530">NT is an independent consultant to the Coalition for Epidemic Preparedness Innovations (CEPI). All other authors are employees of CEPI. CEPI is supporting the research and development of a diverse portfolio of vaccine candidates (including vaccines against Nipah virus) based on a range of vaccine approaches.</p></sec></body><back><ref-list id="bibl10"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="other" id="sbref10"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Prioritizing diseases for research and development in emergency contexts</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts" id="interrefs10">https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts</ext-link><year>2021</year></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book" id="sbref20"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Rota</surname><given-names>PA</given-names></name></person-group><part-title>Henipavirus: ecology, molecular virology, and pathogenesis</part-title><year>2012</year><publisher-name>Springer</publisher-name><publisher-loc>New York, NY</publisher-loc></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="book" id="sbref30"><person-group person-group-type="author"><name name-style="western"><surname>Halpin</surname><given-names>K</given-names></name><name name-style="western"><surname>Rota</surname><given-names>P</given-names></name></person-group><part-title>A review of Hendra virus and Nipah virus infections in man and other animals</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Sing</surname><given-names>A</given-names></name></person-group><source>Zoonoses &#8211; infections affecting humans and animals: focus on public health aspects</source><year>2015</year><publisher-name>Springer</publisher-name><publisher-loc>Dordrecht</publisher-loc><fpage>997</fpage><lpage>1012</lpage></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>N</given-names></name><name name-style="western"><surname>Gushiken</surname><given-names>AC</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kottilil</surname><given-names>S</given-names></name><name name-style="western"><surname>Chua</surname><given-names>JV</given-names></name></person-group><article-title>Evolution of Nipah virus infection: past, present, and future considerations</article-title><source>Trop Med Infect Dis</source><volume>6</volume><year>2021</year><fpage>24</fpage><pub-id pub-id-type="pmid">33672796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/tropicalmed6010024</pub-id><pub-id pub-id-type="pmcid">PMC8005932</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="other" id="sbref50"><person-group person-group-type="author"><collab>Coalition for Epidemic Preparedness Innovations</collab></person-group><article-title>Nipah@20. Proceedings from Nipah Virus International Conference, Singapore, 9 to 11 December 2019</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net/wp-content/uploads/2020/06/2019-CEPI-Duke-WHO-NIAID-Nipah-Conference_FINAL.pdf" id="interrefs20">https://cepi.net/wp-content/uploads/2020/06/2019-CEPI-Duke-WHO-NIAID-Nipah-Conference_FINAL.pdf</ext-link><year>2019</year></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref60"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Nipah virus: risk of importation to the countries of EMR</article-title><source>Wkly Epidemiol Monitor</source><volume>11</volume><year>2018</year><fpage>23</fpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref70"><person-group person-group-type="author"><name name-style="western"><surname>Enchery</surname><given-names>F</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>B</given-names></name></person-group><article-title>Understanding the interaction between henipaviruses and their natural host, fruit bats: paving the way toward control of highly lethal infection in humans</article-title><source>Int Rev Immunol</source><volume>36</volume><year>2017</year><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">28060559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08830185.2016.1255883</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="other" id="sbref80"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Population data by WHO region. Global health observatory repository data</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://apps.who.int/gho/data/view.main.POP2020?lang=en" id="interrefs30">https://apps.who.int/gho/data/view.main.POP2020?lang=en</ext-link><year>2016</year></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref90"><person-group person-group-type="author"><name name-style="western"><surname>Nikolay</surname><given-names>B</given-names></name><name name-style="western"><surname>Salje</surname><given-names>H</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Transmission of Nipah virus&#8212;14 years of investigations in Bangladesh</article-title><source>N Engl J Med</source><volume>380</volume><year>2019</year><fpage>1804</fpage><lpage>1814</lpage><pub-id pub-id-type="pmid">31067370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1805376</pub-id><pub-id pub-id-type="pmcid">PMC6547369</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref100"><person-group person-group-type="author"><name name-style="western"><surname>Sazzad</surname><given-names>HMS</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gurley</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Nipah virus infection outbreak with nosocomial and corpse-to-human transmission, Bangladesh</article-title><source>Emerg Infect Dis</source><volume>19</volume><year>2013</year><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">23347678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1902.120971</pub-id><pub-id pub-id-type="pmcid">PMC3559054</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref110"><person-group person-group-type="author"><name name-style="western"><surname>Koczula</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gallotta</surname><given-names>A</given-names></name></person-group><article-title>Lateral flow assays</article-title><source>Essays Biochem</source><volume>60</volume><year>2016</year><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">27365041</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/EBC20150012</pub-id><pub-id pub-id-type="pmcid">PMC4986465</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref120"><person-group person-group-type="author"><name name-style="western"><surname>Mazzola</surname><given-names>LT</given-names></name><name name-style="western"><surname>Kelly-Cirino</surname><given-names>C</given-names></name></person-group><article-title>Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia</article-title><source>BMJ Glob Health</source><volume>4</volume><issue>suppl 2</issue><year>2019</year><object-id pub-id-type="publisher-id">e001118</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2018-001118</pub-id><pub-id pub-id-type="pmcid">PMC6361328</pub-id><pub-id pub-id-type="pmid">30815286</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="other" id="sbref130"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Nipah research &amp; development (R&amp;D) roadmap</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/nipah-research-and-development-(r-d)-roadmap" id="interrefs40">https://www.who.int/publications/m/item/nipah-research-and-development-(r-d)-roadmap</ext-link><year>2018</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="other" id="sbref140"><person-group person-group-type="author"><collab>BMJ</collab></person-group><article-title>BMJ best practice. Henipaviruses</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bestpractice.bmj.com/topics/en-gb/1607/management-approach" id="interrefs50">https://bestpractice.bmj.com/topics/en-gb/1607/management-approach</ext-link><year>2021</year></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="other" id="sbref150"><person-group person-group-type="author"><collab>Institute of Epidemiology Disease Control And Research</collab></person-group><article-title>National Guideline for management, prevention and control of Nipah virus infection</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://iedcr.gov.bd/publication/guidelines/10adb7d5-b36b-4e87-a37c-7fc981f4f888" id="interrefs60">https://iedcr.gov.bd/publication/guidelines/10adb7d5-b36b-4e87-a37c-7fc981f4f888</ext-link><year>2020</year></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="other" id="sbref160"><person-group person-group-type="author"><collab>Central team Ministry of Health and Family Welfare</collab><collab>Goverment of India</collab></person-group><article-title>Clinical management protocol for Nipah virus disease</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cghealth.nic.in/cghealth17/Information/content/NipahVirus/Treatment.pdf" id="interrefs70">http://cghealth.nic.in/cghealth17/Information/content/NipahVirus/Treatment.pdf</ext-link><year>2018</year></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="other" id="sbref170"><person-group person-group-type="author"><collab>Indian Medical Association&#8211;Tamil Nadu State Branch</collab></person-group><article-title>Surveillance, prevention and control of Nipah virus infection: a practical handbook</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://imatn.com/wp-content/uploads/2018/05/surveillance-prevention-and-control-of-nipah-virus-infection-a-practical-handbook.pdf" id="interrefs80">https://imatn.com/wp-content/uploads/2018/05/surveillance-prevention-and-control-of-nipah-virus-infection-a-practical-handbook.pdf</ext-link><year>2014</year></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sbref180"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>HT</given-names></name><name name-style="western"><surname>Kamarulzman</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>CT</given-names></name><etal/></person-group><article-title>Treatment of acute Nipah encephalitis with ribavirin</article-title><source>Ann Neurol</source><volume>49</volume><year>2001</year><fpage>810</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">11409437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.1062</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sbref190"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Gary</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge</article-title><source>Sci Transl Med</source><volume>11</volume><year>2019</year><object-id pub-id-type="publisher-id">eaau9242</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aau9242</pub-id><pub-id pub-id-type="pmcid">PMC6732787</pub-id><pub-id pub-id-type="pmid">31142680</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="other" id="sbref200"><person-group person-group-type="author"><collab>Reuters</collab></person-group><article-title>FACTBOX&#8211;Countries where remdesivir is approved or supported for treating COVID-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.reuters.com/article/healthcoronavirus-gilead-remdesivir-idUSL1N2HD1UX" id="interrefs90">https://www.reuters.com/article/healthcoronavirus-gilead-remdesivir-idUSL1N2HD1UX</ext-link><year>2021</year></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sbref210"><person-group person-group-type="author"><name name-style="western"><surname>Dawes</surname><given-names>BE</given-names></name><name name-style="western"><surname>Kalveram</surname><given-names>B</given-names></name><name name-style="western"><surname>Ikegami</surname><given-names>T</given-names></name><etal/></person-group><article-title>Favipiravir (T-705) protects against Nipah virus infection in the hamster model</article-title><source>Sci Rep</source><volume>8</volume><year>2018</year><object-id pub-id-type="publisher-id">7604</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-25780-3</pub-id><pub-id pub-id-type="pmcid">PMC5954062</pub-id><pub-id pub-id-type="pmid">29765101</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sbref220"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>U</given-names></name><name name-style="western"><surname>Raju</surname><given-names>R</given-names></name><name name-style="western"><surname>Udwadia</surname><given-names>ZF</given-names></name></person-group><article-title>Favipiravir: a new and emerging antiviral option in COVID-19</article-title><source>Med J Armed Forces India</source><volume>76</volume><year>2020</year><fpage>370</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">32895599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mjafi.2020.08.004</pub-id><pub-id pub-id-type="pmcid">PMC7467067</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sbref230"><person-group person-group-type="author"><name name-style="western"><surname>Freiberg</surname><given-names>AN</given-names></name><name name-style="western"><surname>Worthy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>MR</given-names></name></person-group><article-title>Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection</article-title><source>J Gen Virol</source><volume>91</volume><issue>Pt 3</issue><year>2010</year><fpage>765</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">19889926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/vir.0.017269-0</pub-id><pub-id pub-id-type="pmcid">PMC2888097</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sbref240"><person-group person-group-type="author"><name name-style="western"><surname>Pallister</surname><given-names>J</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Crameri</surname><given-names>G</given-names></name><etal/></person-group><article-title>Chloroquine administration does not prevent Nipah virus infection and disease in ferrets</article-title><source>J Virol</source><volume>83</volume><year>2009</year><fpage>11979</fpage><lpage>11982</lpage><pub-id pub-id-type="pmid">19759137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01847-09</pub-id><pub-id pub-id-type="pmcid">PMC2772715</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sbref250"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>C</given-names></name><name name-style="western"><surname>Dhondt</surname><given-names>KP</given-names></name><name name-style="western"><surname>Chalons</surname><given-names>M</given-names></name><etal/></person-group><article-title>Heparan sulfate-dependent enhancement of henipavirus infection</article-title><source>mBio</source><volume>6</volume><year>2015</year><object-id pub-id-type="publisher-id">e02427</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02427-14</pub-id><pub-id pub-id-type="pmcid">PMC4453572</pub-id><pub-id pub-id-type="pmid">25759505</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sbref260"><person-group person-group-type="author"><name name-style="western"><surname>Georges-Courbot</surname><given-names>MC</given-names></name><name name-style="western"><surname>Contamin</surname><given-names>H</given-names></name><name name-style="western"><surname>Faure</surname><given-names>C</given-names></name><etal/></person-group><article-title>Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection</article-title><source>Antimicrob Agents Chemother</source><volume>50</volume><year>2006</year><fpage>1768</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">16641448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.50.5.1768-1772.2006</pub-id><pub-id pub-id-type="pmcid">PMC1472238</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="other" id="sbref270"><person-group person-group-type="author"><collab>Hemispherx Biopharma</collab></person-group><article-title>Executive informational overview</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdn2.hubspot.net/hubfs/150154/docs/Hemispherx-Executive-Informational-Overview-11-27-16.pdf" id="interrefs100">https://cdn2.hubspot.net/hubfs/150154/docs/Hemispherx-Executive-Informational-Overview-11-27-16.pdf</ext-link><year>Nov 27, 2016</year></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sbref280"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><name name-style="western"><surname>Spengler</surname><given-names>JR</given-names></name><name name-style="western"><surname>Krumpe</surname><given-names>LRH</given-names></name><etal/></person-group><article-title>Griffithsin inhibits Nipah virus entry and fusion and can protect Syrian golden hamsters from lethal Nipah virus challenge</article-title><source>J Infect Dis</source><volume>221</volume><issue>suppl 4</issue><year>2020</year><fpage>S480</fpage><lpage>S492</lpage><pub-id pub-id-type="pmid">32037447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz630</pub-id><pub-id pub-id-type="pmcid">PMC7199786</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="other" id="sbref290"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="interrefs110">ClinicalTrials.gov</ext-link></element-citation><element-citation publication-type="other" id="sbref300"><article-title>Studies found for griffithsin</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/results?recrs=&amp;cond=&amp;term=griffithsin&amp;cntry=&amp;state=&amp;city=&amp;dist" id="interrefs120">https://www.clinicaltrials.gov/ct2/results?recrs=&amp;cond=&amp;term=griffithsin&amp;cntry=&amp;state=&amp;city=&amp;dist</ext-link><year>2021</year></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sbref310"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>C</given-names></name><name name-style="western"><surname>Porotto</surname><given-names>M</given-names></name><name name-style="western"><surname>Figueira</surname><given-names>TN</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>B</given-names></name><name name-style="western"><surname>Moscona</surname><given-names>A</given-names></name></person-group><article-title>Fusion inhibitory lipopeptides engineered for prophylaxis of Nipah virus in primates</article-title><source>J Infect Dis</source><volume>218</volume><year>2018</year><fpage>218</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">29566184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiy152</pub-id><pub-id pub-id-type="pmcid">PMC6009590</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sbref320"><person-group person-group-type="author"><name name-style="western"><surname>Porotto</surname><given-names>M</given-names></name><name name-style="western"><surname>Rockx</surname><given-names>B</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry</article-title><source>PLoS Pathog</source><volume>6</volume><year>2010</year><object-id pub-id-type="publisher-id">e1001168</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1001168</pub-id><pub-id pub-id-type="pmcid">PMC2965769</pub-id><pub-id pub-id-type="pmid">21060819</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sbref330"><person-group person-group-type="author"><name name-style="western"><surname>Aljofan</surname><given-names>M</given-names></name><name name-style="western"><surname>Sganga</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro</article-title><source>Virol J</source><volume>6</volume><year>2009</year><fpage>187</fpage><pub-id pub-id-type="pmid">19889218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-6-187</pub-id><pub-id pub-id-type="pmcid">PMC2781006</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sbref340"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YE</given-names></name><name name-style="western"><surname>Park</surname><given-names>A</given-names></name><name name-style="western"><surname>Lake</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding</article-title><source>PLoS Pathog</source><volume>6</volume><year>2010</year><object-id pub-id-type="publisher-id">e1001186</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1001186</pub-id><pub-id pub-id-type="pmcid">PMC2978725</pub-id><pub-id pub-id-type="pmid">21085610</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sbref350"><person-group person-group-type="author"><name name-style="western"><surname>Hotard</surname><given-names>AL</given-names></name><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Nichol</surname><given-names>ST</given-names></name><name name-style="western"><surname>Spiropoulou</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name></person-group><article-title>4&#8242;-azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency</article-title><source>Antiviral Res</source><volume>144</volume><year>2017</year><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">28629988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2017.06.011</pub-id><pub-id pub-id-type="pmcid">PMC5648002</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="other" id="sbref360"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="interrefs130">ClinicalTrials.gov</ext-link></element-citation><element-citation publication-type="other" id="sbref370"><article-title>A study of balapiravir in patients with dengue virus infection</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01096576" id="interrefs140">https://clinicaltrials.gov/ct2/show/NCT01096576</ext-link><year>2021</year></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sbref380"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><name name-style="western"><surname>Amblard</surname><given-names>F</given-names></name><name name-style="western"><surname>Flint</surname><given-names>M</given-names></name><etal/></person-group><article-title>Potent in vitro activity of beta-D-4&#8242;-chloromethyl-2&#8242;-deoxy-2&#8242;-fluorocytidine against Nipah virus</article-title><source>Antiviral Res</source><volume>175</volume><year>2020</year><object-id pub-id-type="publisher-id">104712</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104712</pub-id><pub-id pub-id-type="pmcid">PMC7054849</pub-id><pub-id pub-id-type="pmid">31935422</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="other" id="sbref390"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="interrefs150">ClinicalTrials.gov</ext-link></element-citation><element-citation publication-type="other" id="sbref400"><article-title>7 studies found for lumicitabine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/results?recrs=&amp;cond=&amp;term=lumicitabine&amp;cntry=&amp;state=&amp;city=&amp;dist" id="interrefs160">https://www.clinicaltrials.gov/ct2/results?recrs=&amp;cond=&amp;term=lumicitabine&amp;cntry=&amp;state=&amp;city=&amp;dist</ext-link><year>2021</year></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sbref410"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Aliyari</surname><given-names>R</given-names></name><name name-style="western"><surname>Chikere</surname><given-names>K</given-names></name><etal/></person-group><article-title>Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol</article-title><source>Immunity</source><volume>38</volume><year>2013</year><fpage>92</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">23273844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2012.11.005</pub-id><pub-id pub-id-type="pmcid">PMC3698975</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sbref420"><person-group person-group-type="author"><name name-style="western"><surname>Pattabhi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>CR</given-names></name><name name-style="western"><surname>Dong</surname><given-names>R</given-names></name><etal/></person-group><article-title>Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway</article-title><source>J Virol</source><volume>90</volume><year>2015</year><fpage>2372</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">26676770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02202-15</pub-id><pub-id pub-id-type="pmcid">PMC4810700</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sbref430"><person-group person-group-type="author"><name name-style="western"><surname>Tigabu</surname><given-names>B</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>L</given-names></name><name name-style="western"><surname>White</surname><given-names>EL</given-names></name><etal/></person-group><article-title>A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus</article-title><source>Assay Drug Dev Technol</source><volume>12</volume><year>2014</year><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">24735442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/adt.2013.567</pub-id><pub-id pub-id-type="pmcid">PMC3994909</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sbref440"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>N</given-names></name><name name-style="western"><surname>Kanitkar</surname><given-names>TR</given-names></name><name name-style="western"><surname>Roy</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Predicting and designing therapeutics against the Nipah virus</article-title><source>PLoS Negl Trop Dis</source><volume>13</volume><year>2019</year><object-id pub-id-type="publisher-id">e0007419</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0007419</pub-id><pub-id pub-id-type="pmcid">PMC6907750</pub-id><pub-id pub-id-type="pmid">31830030</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sbref450"><person-group person-group-type="author"><name name-style="western"><surname>Porotto</surname><given-names>M</given-names></name><name name-style="western"><surname>Orefice</surname><given-names>G</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy</article-title><source>J Virol</source><volume>83</volume><year>2009</year><fpage>5148</fpage><lpage>5155</lpage><pub-id pub-id-type="pmid">19264786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00164-09</pub-id><pub-id pub-id-type="pmcid">PMC2682105</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sbref460"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>CT</given-names></name><name name-style="western"><surname>Goh</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Wong</surname><given-names>KT</given-names></name><etal/></person-group><article-title>Relapsed and late-onset Nipah encephalitis</article-title><source>Ann Neurol</source><volume>51</volume><year>2002</year><fpage>703</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">12112075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.10212</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sbref470"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Niyas</surname><given-names>VKM</given-names></name><name name-style="western"><surname>Soneja</surname><given-names>M</given-names></name><etal/></person-group><article-title>First experience of ribavirin postexposure prophylaxis for Nipah virus, tried during the 2018 outbreak in Kerala, India</article-title><source>J Infect</source><volume>78</volume><year>2019</year><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2019.03.005</pub-id><pub-id pub-id-type="pmid">30851290</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="other" id="sbref480"><person-group person-group-type="author"><collab>Times of India</collab></person-group><article-title>Ribavirin effective in treating Nipah, say Pune scientists</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://timesofindia.indiatimes.com/india/ribavirin-effective-in-treating-nipah-say-pune-scientists/articleshow/64456461.cms" id="interrefs170">https://timesofindia.indiatimes.com/india/ribavirin-effective-in-treating-nipah-say-pune-scientists/articleshow/64456461.cms</ext-link><year>2018</year></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sbref490"><person-group person-group-type="author"><name name-style="western"><surname>Bonaparte</surname><given-names>MI</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>AS</given-names></name><name name-style="western"><surname>Bossart</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus</article-title><source>Proc Natl Acad Sci USA</source><volume>102</volume><year>2005</year><fpage>10652</fpage><lpage>10657</lpage><pub-id pub-id-type="pmid">15998730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0504887102</pub-id><pub-id pub-id-type="pmcid">PMC1169237</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sbref500"><person-group person-group-type="author"><name name-style="western"><surname>Bossart</surname><given-names>KN</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>TW</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name><etal/></person-group><article-title>A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge</article-title><source>Sci Transl Med</source><volume>3</volume><year>2011</year><object-id pub-id-type="publisher-id">105ra3</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3002901</pub-id><pub-id pub-id-type="pmcid">PMC3313625</pub-id><pub-id pub-id-type="pmid">22013123</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sbref510"><person-group person-group-type="author"><name name-style="western"><surname>Bossart</surname><given-names>KN</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><etal/></person-group><article-title>A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection</article-title><source>PLoS Pathog</source><volume>5</volume><year>2009</year><object-id pub-id-type="publisher-id">e1000642</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1000642</pub-id><pub-id pub-id-type="pmcid">PMC2765826</pub-id><pub-id pub-id-type="pmid">19888339</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sbref520"><person-group person-group-type="author"><name name-style="western"><surname>Geisbert</surname><given-names>TW</given-names></name><name name-style="western"><surname>Mire</surname><given-names>CE</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody</article-title><source>Sci Transl Med</source><volume>6</volume><year>2014</year><object-id pub-id-type="publisher-id">242ra82</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3008929</pub-id><pub-id pub-id-type="pmcid">PMC4467163</pub-id><pub-id pub-id-type="pmid">24964990</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sbref530"><person-group person-group-type="author"><name name-style="western"><surname>Playford</surname><given-names>EG</given-names></name><name name-style="western"><surname>Munro</surname><given-names>T</given-names></name><name name-style="western"><surname>Mahler</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>445</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">32027842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(19)30634-6</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sbref540"><person-group person-group-type="author"><name name-style="western"><surname>Dang</surname><given-names>HV</given-names></name><name name-style="western"><surname>Chan</surname><given-names>YP</given-names></name><name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections</article-title><source>Nat Struct Mol Biol</source><volume>26</volume><year>2019</year><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">31570878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41594-019-0308-9</pub-id><pub-id pub-id-type="pmcid">PMC6858553</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sbref550"><person-group person-group-type="author"><name name-style="western"><surname>Mire</surname><given-names>CE</given-names></name><name name-style="western"><surname>Chan</surname><given-names>YP</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>V</given-names></name><etal/></person-group><article-title>A cross-reactive humanized monoclonal antibody targeting fusion glycoprotein function protects ferrets against lethal Nipah virus and Hendra virus infection</article-title><source>J Infect Dis</source><volume>221</volume><issue>suppl 4</issue><year>2020</year><fpage>S471</fpage><lpage>S479</lpage><pub-id pub-id-type="pmid">31686101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz515</pub-id><pub-id pub-id-type="pmcid">PMC7199785</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sbref560"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Cross</surname><given-names>RW</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Potent henipavirus neutralization by antibodies recognizing diverse sites on Hendra and Nipah virus receptor binding protein</article-title><source>Cell</source><volume>183</volume><year>2020</year><fpage>1536</fpage><comment>50.e17</comment><pub-id pub-id-type="pmid">33306954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.11.023</pub-id><pub-id pub-id-type="pmcid">PMC7771633</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sbref570"><person-group person-group-type="author"><name name-style="western"><surname>Guillaume</surname><given-names>V</given-names></name><name name-style="western"><surname>Contamin</surname><given-names>H</given-names></name><name name-style="western"><surname>Loth</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antibody prophylaxis and therapy against Nipah virus infection in hamsters</article-title><source>J Virol</source><volume>80</volume><year>2006</year><fpage>1972</fpage><lpage>1978</lpage><pub-id pub-id-type="pmid">16439553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.80.4.1972-1978.2006</pub-id><pub-id pub-id-type="pmcid">PMC1367164</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="other" id="sbref580"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO target product profile for Nipah virus vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/Nipah_virus_vaccineTPP.pdf?ua=1" id="interrefs180">https://www.who.int/blueprint/priority-diseases/key-action/Nipah_virus_vaccineTPP.pdf?ua=1</ext-link><year>2017</year></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sbref590"><person-group person-group-type="author"><name name-style="western"><surname>Tamin</surname><given-names>A</given-names></name><name name-style="western"><surname>Harcourt</surname><given-names>BH</given-names></name><name name-style="western"><surname>Ksiazek</surname><given-names>TG</given-names></name><name name-style="western"><surname>Rollin</surname><given-names>PE</given-names></name><name name-style="western"><surname>Bellini</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Rota</surname><given-names>PA</given-names></name></person-group><article-title>Functional properties of the fusion and attachment glycoproteins of Nipah virus</article-title><source>Virology</source><volume>296</volume><year>2002</year><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">12036330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/viro.2002.1418</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sbref600"><person-group person-group-type="author"><name name-style="western"><surname>Guillaume</surname><given-names>V</given-names></name><name name-style="western"><surname>Contamin</surname><given-names>H</given-names></name><name name-style="western"><surname>Loth</surname><given-names>P</given-names></name><etal/></person-group><article-title>Nipah virus: vaccination and passive protection studies in a hamster model</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>834</fpage><lpage>840</lpage><pub-id pub-id-type="pmid">14694115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.2.834-840.2004</pub-id><pub-id pub-id-type="pmcid">PMC368848</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sbref610"><person-group person-group-type="author"><name name-style="western"><surname>Weingartl</surname><given-names>HM</given-names></name><name name-style="western"><surname>Berhane</surname><given-names>Y</given-names></name><name name-style="western"><surname>Caswell</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Recombinant Nipah virus vaccines protect pigs against challenge</article-title><source>J Virol</source><volume>80</volume><year>2006</year><fpage>7929</fpage><lpage>7938</lpage><pub-id pub-id-type="pmid">16873250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00263-06</pub-id><pub-id pub-id-type="pmcid">PMC1563797</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sbref620"><person-group person-group-type="author"><name name-style="western"><surname>Tamin</surname><given-names>A</given-names></name><name name-style="western"><surname>Harcourt</surname><given-names>BH</given-names></name><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Development of a neutralization assay for Nipah virus using pseudotype particles</article-title><source>J Virol Methods</source><volume>160</volume><year>2009</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19559943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jviromet.2009.02.025</pub-id><pub-id pub-id-type="pmcid">PMC2704486</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sbref630"><person-group person-group-type="author"><name name-style="western"><surname>Defang</surname><given-names>GN</given-names></name><name name-style="western"><surname>Khetawat</surname><given-names>D</given-names></name><name name-style="western"><surname>Broder</surname><given-names>CC</given-names></name><name name-style="western"><surname>Quinnan</surname><given-names>GV</given-names><suffix>Jr</suffix></name></person-group><article-title>Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system</article-title><source>Vaccine</source><volume>29</volume><year>2010</year><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">21050901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.10.053</pub-id><pub-id pub-id-type="pmcid">PMC3032421</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sbref640"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>A</given-names></name><name name-style="western"><surname>Rose</surname><given-names>JK</given-names></name></person-group><article-title>Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach</article-title><source>J Virol</source><volume>85</volume><year>2011</year><fpage>2004</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">21177820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01852-10</pub-id><pub-id pub-id-type="pmcid">PMC3067786</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sbref650"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Su</surname><given-names>H</given-names></name><etal/></person-group><article-title>Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs</article-title><source>Virology</source><volume>432</volume><year>2012</year><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">22726244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2012.06.001</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sbref660"><person-group person-group-type="author"><name name-style="western"><surname>Mire</surname><given-names>CE</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>KM</given-names></name><name name-style="western"><surname>Cross</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease</article-title><source>Virol J</source><volume>10</volume><year>2013</year><fpage>e353</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-10-353</pub-id><pub-id pub-id-type="pmcid">PMC3878732</pub-id><pub-id pub-id-type="pmid">24330654</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sbref670"><person-group person-group-type="author"><name name-style="western"><surname>Ploquin</surname><given-names>A</given-names></name><name name-style="western"><surname>Szecsi</surname><given-names>J</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Protection against henipavirus infection by use of recombinant adeno-associated virus&#8211;vector vaccines</article-title><source>J Infect Dis</source><volume>207</volume><year>2013</year><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">23175762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jis699</pub-id><pub-id pub-id-type="pmcid">PMC7107322</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sbref680"><person-group person-group-type="author"><name name-style="western"><surname>Yoneda</surname><given-names>M</given-names></name><name name-style="western"><surname>Georges-Courbot</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>F</given-names></name><etal/></person-group><article-title>Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e58414</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0058414</pub-id><pub-id pub-id-type="pmcid">PMC3597623</pub-id><pub-id pub-id-type="pmid">23516477</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sbref690"><person-group person-group-type="author"><name name-style="western"><surname>DeBuysscher</surname><given-names>BL</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D</given-names></name><name name-style="western"><surname>Marzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>J</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name></person-group><article-title>Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>2637</fpage><lpage>2644</lpage><pub-id pub-id-type="pmid">24631094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.02.087</pub-id><pub-id pub-id-type="pmcid">PMC4829066</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sbref700"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><name name-style="western"><surname>Bird</surname><given-names>BH</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters</article-title><source>Antiviral Res</source><volume>101</volume><year>2014</year><fpage>26</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">24184127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2013.10.012</pub-id><pub-id pub-id-type="pmcid">PMC3874889</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sbref710"><person-group person-group-type="author"><name name-style="western"><surname>Kurup</surname><given-names>D</given-names></name><name name-style="western"><surname>Wirblich</surname><given-names>C</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Marzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Schnell</surname><given-names>MJ</given-names></name></person-group><article-title>Rhabdovirus-based vaccine platforms against henipaviruses</article-title><source>J Virol</source><volume>89</volume><year>2015</year><fpage>144</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">25320306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02308-14</pub-id><pub-id pub-id-type="pmcid">PMC4301098</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sbref720"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>J</given-names></name><name name-style="western"><surname>DeBuysscher</surname><given-names>BL</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name><etal/></person-group><article-title>Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease</article-title><source>Vaccine</source><volume>33</volume><year>2015</year><fpage>2823</fpage><lpage>2829</lpage><pub-id pub-id-type="pmid">25865472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.03.089</pub-id><pub-id pub-id-type="pmcid">PMC4433813</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sbref730"><person-group person-group-type="author"><name name-style="western"><surname>DeBuysscher</surname><given-names>BL</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>T</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>J</given-names></name></person-group><article-title>Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine</article-title><source>NPJ Vaccines</source><volume>1</volume><year>2016</year><object-id pub-id-type="publisher-id">16002</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjvaccines.2016.2</pub-id><pub-id pub-id-type="pmcid">PMC5505655</pub-id><pub-id pub-id-type="pmid">28706736</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sbref740"><person-group person-group-type="author"><name name-style="western"><surname>Guillaume-Vasselin</surname><given-names>V</given-names></name><name name-style="western"><surname>Lemaitre</surname><given-names>L</given-names></name><name name-style="western"><surname>Dhondt</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Protection from Hendra virus infection with canarypox recombinant vaccine</article-title><source>NPJ Vaccines</source><volume>1</volume><year>2016</year><object-id pub-id-type="publisher-id">16003</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjvaccines.2016.3</pub-id><pub-id pub-id-type="pmcid">PMC5707888</pub-id><pub-id pub-id-type="pmid">29263849</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sbref750"><person-group person-group-type="author"><name name-style="western"><surname>van den Pol</surname><given-names>AN</given-names></name><name name-style="western"><surname>Mao</surname><given-names>G</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>A</given-names></name><name name-style="western"><surname>Rose</surname><given-names>JK</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JN</given-names></name></person-group><article-title>Chikungunya, influenza, Nipah, and Semliki Forest chimeric viruses with vesicular stomatitis virus: actions in the brain</article-title><source>J Virol</source><volume>91</volume><year>2017</year><fpage>e02154</fpage><lpage>e02160</lpage><pub-id pub-id-type="pmid">28077641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02154-16</pub-id><pub-id pub-id-type="pmcid">PMC5331823</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sbref760"><person-group person-group-type="author"><name name-style="western"><surname>Keshwara</surname><given-names>R</given-names></name><name name-style="western"><surname>Shiels</surname><given-names>T</given-names></name><name name-style="western"><surname>Postnikova</surname><given-names>E</given-names></name><etal/></person-group><article-title>Rabies-based vaccine induces potent immune responses against Nipah virus</article-title><source>NPJ Vaccines</source><volume>4</volume><year>2019</year><fpage>15</fpage><pub-id pub-id-type="pmid">31016033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-019-0109-5</pub-id><pub-id pub-id-type="pmcid">PMC6465360</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sbref770"><person-group person-group-type="author"><name name-style="western"><surname>Mire</surname><given-names>CE</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>JB</given-names></name><name name-style="western"><surname>Agans</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Use of single-injection recombinant vesicular stomatitis virus vaccine to protect nonhuman primates against lethal Nipah virus disease</article-title><source>Emerg Infect Dis</source><volume>25</volume><year>2019</year><fpage>1144</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">31107231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2506.181620</pub-id><pub-id pub-id-type="pmcid">PMC6537706</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sbref780"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S</given-names></name><etal/></person-group><article-title>A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters</article-title><source>PLoS Negl Trop Dis</source><volume>13</volume><year>2019</year><object-id pub-id-type="publisher-id">e0007462</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0007462</pub-id><pub-id pub-id-type="pmcid">PMC6581282</pub-id><pub-id pub-id-type="pmid">31170144</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sbref790"><person-group person-group-type="author"><name name-style="western"><surname>Kalodimou</surname><given-names>G</given-names></name><name name-style="western"><surname>Veit</surname><given-names>S</given-names></name><name name-style="western"><surname>Jany</surname><given-names>S</given-names></name><etal/></person-group><article-title>A soluble version of Nipah virus glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T Cells in mice</article-title><source>Viruses</source><volume>12</volume><year>2019</year><fpage>26</fpage><pub-id pub-id-type="pmid">31878180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12010026</pub-id><pub-id pub-id-type="pmcid">PMC7019319</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sbref800"><person-group person-group-type="author"><name name-style="western"><surname>Shuai</surname><given-names>L</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Bu</surname><given-names>Z</given-names></name></person-group><article-title>Immune responses in mice and pigs after oral vaccination with rabies virus vectored Nipah disease vaccines</article-title><source>Vet Microbiol</source><volume>241</volume><year>2020</year><object-id pub-id-type="publisher-id">108549</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2019.108549</pub-id><pub-id pub-id-type="pmid">31928698</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sbref810"><person-group person-group-type="author"><name name-style="western"><surname>Pedrera</surname><given-names>M</given-names></name><name name-style="western"><surname>Macchi</surname><given-names>F</given-names></name><name name-style="western"><surname>McLean</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Bovine herpesvirus-4-vectored delivery of Nipah virus glycoproteins enhances T cell immunogenicity in pigs</article-title><source>Vaccines</source><volume>8</volume><year>2020</year><fpage>115</fpage><pub-id pub-id-type="pmid">32131403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8010115</pub-id><pub-id pub-id-type="pmcid">PMC7157636</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sbref820"><person-group person-group-type="author"><name name-style="western"><surname>Mungall</surname><given-names>BA</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Crameri</surname><given-names>G</given-names></name><etal/></person-group><article-title>Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine</article-title><source>J Virol</source><volume>80</volume><year>2006</year><fpage>12293</fpage><lpage>12302</lpage><pub-id pub-id-type="pmid">17005664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01619-06</pub-id><pub-id pub-id-type="pmcid">PMC1676295</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sbref830"><person-group person-group-type="author"><name name-style="western"><surname>McEachern</surname><given-names>JA</given-names></name><name name-style="western"><surname>Bingham</surname><given-names>J</given-names></name><name name-style="western"><surname>Crameri</surname><given-names>G</given-names></name><etal/></person-group><article-title>A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>3842</fpage><lpage>3852</lpage><pub-id pub-id-type="pmid">18556094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.05.016</pub-id><pub-id pub-id-type="pmcid">PMC6186147</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sbref840"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>YP</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S</given-names></name><etal/></person-group><article-title>Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins</article-title><source>J Virol</source><volume>86</volume><year>2012</year><fpage>11457</fpage><lpage>11471</lpage><pub-id pub-id-type="pmid">22915804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01318-12</pub-id><pub-id pub-id-type="pmcid">PMC3486283</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sbref850"><person-group person-group-type="author"><name name-style="western"><surname>Bossart</surname><given-names>KN</given-names></name><name name-style="western"><surname>Rockx</surname><given-names>B</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name><etal/></person-group><article-title>A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge</article-title><source>Sci Transl Med</source><volume>4</volume><year>2012</year><object-id pub-id-type="publisher-id">146ra07</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.3004241</pub-id><pub-id pub-id-type="pmcid">PMC3516289</pub-id><pub-id pub-id-type="pmid">22875827</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sbref860"><person-group person-group-type="author"><name name-style="western"><surname>Pallister</surname><given-names>JA</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R</given-names></name><name name-style="western"><surname>Arkinstall</surname><given-names>R</given-names></name><etal/></person-group><article-title>Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months</article-title><source>Virol J</source><volume>10</volume><year>2013</year><fpage>e237</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-10-237</pub-id><pub-id pub-id-type="pmcid">PMC3718761</pub-id><pub-id pub-id-type="pmid">23867060</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sbref870"><person-group person-group-type="author"><name name-style="western"><surname>Mire</surname><given-names>CE</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>JB</given-names></name><name name-style="western"><surname>Agans</surname><given-names>KN</given-names></name><etal/></person-group><article-title>A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge</article-title><source>J Virol</source><volume>88</volume><year>2014</year><fpage>4624</fpage><lpage>4631</lpage><pub-id pub-id-type="pmid">24522928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00005-14</pub-id><pub-id pub-id-type="pmcid">PMC3993805</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sbref880"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Pallister</surname><given-names>J</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health</article-title><source>Emerg Infect Dis</source><volume>20</volume><year>2014</year><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">24572697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid2003.131159</pub-id><pub-id pub-id-type="pmcid">PMC3944873</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sbref890"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>R</given-names></name><name name-style="western"><surname>Hodge</surname><given-names>A</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R</given-names></name><etal/></person-group><article-title>Virus-neutralising antibody responses in horses following vaccination with Equivac(R) HeV: a field study</article-title><source>Aust Vet J</source><volume>96</volume><year>2018</year><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">29691855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/avj.12694</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sbref900"><person-group person-group-type="author"><name name-style="western"><surname>Pickering</surname><given-names>BS</given-names></name><name name-style="western"><surname>Hardham</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><etal/></person-group><article-title>Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>4777</fpage><lpage>4786</lpage><pub-id pub-id-type="pmid">27544586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.08.028</pub-id><pub-id pub-id-type="pmcid">PMC6161494</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sbref910"><person-group person-group-type="author"><name name-style="western"><surname>Pallister</surname><given-names>J</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LF</given-names></name><etal/></person-group><article-title>A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>5623</fpage><lpage>5630</lpage><pub-id pub-id-type="pmid">21689706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.06.015</pub-id><pub-id pub-id-type="pmcid">PMC3153950</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sbref920"><person-group person-group-type="author"><name name-style="western"><surname>Loomis</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Stewart-Jones</surname><given-names>GBE</given-names></name><name name-style="western"><surname>Tsybovsky</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structure-based design of Nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><fpage>842</fpage><pub-id pub-id-type="pmid">32595632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00842</pub-id><pub-id pub-id-type="pmcid">PMC7300195</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sbref930"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fc-based recombinant henipavirus vaccines elicit broad neutralizing antibody responses in mice</article-title><source>Viruses</source><volume>12</volume><year>2020</year><fpage>480</fpage><pub-id pub-id-type="pmid">32340278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12040480</pub-id><pub-id pub-id-type="pmcid">PMC7232446</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sbref940"><person-group person-group-type="author"><name name-style="western"><surname>Geisbert</surname><given-names>TW</given-names></name><name name-style="western"><surname>Bobb</surname><given-names>K</given-names></name><name name-style="western"><surname>Borisevich</surname><given-names>V</given-names></name><etal/></person-group><article-title>A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus</article-title><source>NPJ Vaccines</source><volume>6</volume><year>2021</year><fpage>23</fpage><pub-id pub-id-type="pmid">33558494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-021-00284-w</pub-id><pub-id pub-id-type="pmcid">PMC7870971</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sbref950"><person-group person-group-type="author"><name name-style="western"><surname>Walpita</surname><given-names>P</given-names></name><name name-style="western"><surname>Barr</surname><given-names>J</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M</given-names></name><name name-style="western"><surname>Basler</surname><given-names>CF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Vaccine potential of Nipah virus-like particles</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e18437</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0018437</pub-id><pub-id pub-id-type="pmcid">PMC3071823</pub-id><pub-id pub-id-type="pmid">21494680</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sbref960"><person-group person-group-type="author"><name name-style="western"><surname>Walpita</surname><given-names>P</given-names></name><name name-style="western"><surname>Cong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name><etal/></person-group><article-title>A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model</article-title><source>NPJ Vaccines</source><volume>2</volume><year>2017</year><fpage>21</fpage><pub-id pub-id-type="pmid">29263876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-017-0023-7</pub-id><pub-id pub-id-type="pmcid">PMC5627259</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sbref970"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>R</given-names></name><name name-style="western"><surname>Beltzig</surname><given-names>LC</given-names></name><name name-style="western"><surname>Sawatsky</surname><given-names>B</given-names></name><etal/></person-group><article-title>Generation of therapeutic antisera for emerging viral infections</article-title><source>NPJ Vaccines</source><volume>3</volume><year>2018</year><fpage>42</fpage><pub-id pub-id-type="pmid">30323953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-018-0082-4</pub-id><pub-id pub-id-type="pmcid">PMC6173733</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sbref980"><person-group person-group-type="author"><name name-style="western"><surname>Stroh</surname><given-names>E</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K</given-names></name><name name-style="western"><surname>Schwaiger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice</article-title><source>Vet Microbiol</source><volume>237</volume><year>2019</year><object-id pub-id-type="publisher-id">108405</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2019.108405</pub-id><pub-id pub-id-type="pmid">31561922</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sbref990"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><name name-style="western"><surname>Ge</surname><given-names>JY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>QH</given-names></name><name name-style="western"><surname>Qin</surname><given-names>LT</given-names></name><name name-style="western"><surname>Bu</surname><given-names>ZG</given-names></name></person-group><article-title>[Study of fusion protein and attachment glycoprotein of Nipah virus expressed in recombinant baculovirus]</article-title><source>Sheng Wu Gong Cheng Xue Bao</source><volume>22</volume><year>2006</year><fpage>418</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">16755921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1872-2075(06)60038-1</pub-id><pub-id pub-id-type="pmcid">PMC7148955</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sbref1000"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy of DNA immunization with F and G protein genes of Nipah virus</article-title><source>Ann N Y Acad Sci</source><volume>1081</volume><year>2006</year><fpage>243</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">17135518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1373.029</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sbref1010"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities</article-title><source>Emerg Microbes Infect</source><volume>8</volume><year>2019</year><fpage>272</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">30866781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2019.1571871</pub-id><pub-id pub-id-type="pmcid">PMC6455126</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sbref1020"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>MK</given-names></name><name name-style="western"><surname>Spengler</surname><given-names>JR</given-names></name><name name-style="western"><surname>Welch</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Evaluation of a single-dose nucleoside-modified messenger RNA vaccine encoding Hendra virus-soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters</article-title><source>J Infect Dis</source><volume>221</volume><issue>suppl 4</issue><year>2020</year><fpage>S493</fpage><lpage>S498</lpage><pub-id pub-id-type="pmid">31751453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz553</pub-id><pub-id pub-id-type="pmcid">PMC7368163</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="other" id="sbref1030"><person-group person-group-type="author"><collab>Moderna</collab></person-group><article-title>Press releases. Moderna provides business update and announces three new development programs in infectious disease vaccines</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-business-update-and-announces-three-new" id="interrefs190">https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-business-update-and-announces-three-new</ext-link><year>2021</year></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="other" id="sbref1040"><person-group person-group-type="author"><collab>Coalition for Epidemic Preparedness Innovations</collab></person-group><article-title>CEPI-funded Nipah virus vaccine candidate first to reach phase 1 clinical trial</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-funded-nipah-virus-vaccine-candidate-first-to-reach-phase-1-clinical-trial/" id="interrefs200">https://cepi.net/news_cepi/cepi-funded-nipah-virus-vaccine-candidate-first-to-reach-phase-1-clinical-trial/</ext-link><year>2020</year></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sbref1050"><person-group person-group-type="author"><name name-style="western"><surname>Jusu</surname><given-names>MO</given-names></name><name name-style="western"><surname>Glauser</surname><given-names>G</given-names></name><name name-style="western"><surname>Seward</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Rapid establishment of a cold chain capacity of &#8211;60&#176;C or colder for the STRIVE Ebola vaccine trial during the Ebola outbreak in Sierra Leone</article-title><source>J Infect Dis</source><volume>217</volume><issue>suppl 1</issue><year>2018</year><fpage>S48</fpage><lpage>S55</lpage><pub-id pub-id-type="pmid">29788339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jix336</pub-id><pub-id pub-id-type="pmcid">PMC6927859</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="other" id="sbref1060"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>NIH RePORTER. Project details. Project 2 &#8211; Vanderbilt University</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://reporter.nih.gov/project-details/9897483" id="interrefs210">https://reporter.nih.gov/project-details/9897483</ext-link><year>2021</year></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="other" id="sbref1070"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>NIH RePORTER. Project details. Advancement of vaccines and therapies for henipaviruses</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://reporter.nih.gov/project-details/9897467" id="interrefs220">https://reporter.nih.gov/project-details/9897467</ext-link><year>2021</year></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="other" id="sbref1080"><person-group person-group-type="author"><collab>NIH</collab></person-group><article-title>NIH RePORTER. Project details. Rapid development of vaccines for emerging viruses</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://reporter.nih.gov/project-details/10273019" id="interrefs230">https://reporter.nih.gov/project-details/10273019</ext-link><year>2021</year></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="other" id="sbref1090"><person-group person-group-type="author"><collab>Coalition for Epidemic Preparedness Innovations (CEPI)</collab></person-group><article-title>The urgency of now</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net/wp-content/uploads/2021/03/CEPI_3.5_billion_investment_case_10032021.pdf" id="interrefs240">https://cepi.net/wp-content/uploads/2021/03/CEPI_3.5_billion_investment_case_10032021.pdf</ext-link><year>2021</year></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sbref1100"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="pmid">32227757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2005630</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="other" id="sbref1110"><person-group person-group-type="author"><collab>Clinical Trials Arena</collab></person-group><article-title>Eli Lilly's monoclonal antibody bamlanivimab value allows payer grace for Covid-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrialsarena.com/comment/eli-lillys-monoclonal-antibody-bamlanivimab/#:~:text=Lilly%20will%20be%20supplying%20300%2C000,press%20release%20and%20CEO%20note" id="interrefs250">https://www.clinicaltrialsarena.com/comment/eli-lillys-monoclonal-antibody-bamlanivimab/#:~:text=Lilly%20will%20be%20supplying%20300%2C000,press%20release%20and%20CEO%20note</ext-link><year>2020</year></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="other" id="sbref1120"><person-group person-group-type="author"><collab>Eli Lilly</collab></person-group><article-title>News release. Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. Government to treat COVID-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investor.lilly.com/news-releases/news-release-details/lilly-announces-650000-additional-doses-neutralizing-antibody" id="interrefs260">https://investor.lilly.com/news-releases/news-release-details/lilly-announces-650000-additional-doses-neutralizing-antibody</ext-link><year>2020</year></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="book" id="sbref1130"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>CY</given-names></name><name name-style="western"><surname>McGinley</surname><given-names>L</given-names></name></person-group><part-title>Experimental drug given to Trump to treat covid-19 wins FDA clearance</part-title><year>2020</year><publisher-name>The Seattle Times</publisher-name><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.seattletimes.com/nation-world/experimental-drug-given-to-trump-to-treat-covid-19-wins-fda-clearance/" id="interrefs270">https://www.seattletimes.com/nation-world/experimental-drug-given-to-trump-to-treat-covid-19-wins-fda-clearance/</ext-link></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="other" id="sbref1140"><person-group person-group-type="author"><collab>Statista</collab></person-group><article-title>The cost per jab of Covid-19 vaccine candidates</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statista.com/chart/23658/reported-cost-per-dose-of-covid-19-vaccines/" id="interrefs280">https://www.statista.com/chart/23658/reported-cost-per-dose-of-covid-19-vaccines/</ext-link><year>2020</year></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sbref1150"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Yap</surname><given-names>J</given-names></name><name name-style="western"><surname>Cook</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks</article-title><source>N Engl J Med</source><volume>362</volume><year>2010</year><fpage>2166</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">20558367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0908482</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="other" id="sbref1160"><person-group person-group-type="author"><collab>Regeneron</collab></person-group><article-title>Press Release. Phase 3 prevention trial showed 81% reduced risk of symptomatic Sars-cov-2 infections with subcutaneous administration of Regen-cov&#8482; (casirivimab with imdevimab)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars" id="interrefs290">https://investor.regeneron.com/news-releases/news-release-details/phase-3-prevention-trial-showed-81-reduced-risk-symptomatic-sars</ext-link><year>2021</year></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sbref1170"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name></person-group><article-title>Monoclonal antibodies to disrupt progression of early Covid-19 infection</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>289</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">33471984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMe2034495</pub-id><pub-id pub-id-type="pmcid">PMC7844860</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sbref1180"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>J</given-names></name><name name-style="western"><surname>Abzug</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wattier</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Initial guidance on use of monoclonal antibody therapy for treatment of COVID-19 in children and adolescents</article-title><source>J Pediatric Infect Dis Soc</source><volume>10</volume><year>2021</year><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">33388760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpids/piaa175</pub-id><pub-id pub-id-type="pmcid">PMC7799019</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sbref1190"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>K</given-names></name><name name-style="western"><surname>Ozaltin</surname><given-names>A</given-names></name><name name-style="western"><surname>Mallow</surname><given-names>M</given-names></name><etal/></person-group><article-title>The costs of delivering vaccines in low- and middle-income countries: findings from a systematic review</article-title><source>Vaccine X</source><volume>2</volume><year>2019</year><object-id pub-id-type="publisher-id">100034</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvacx.2019.100034</pub-id><pub-id pub-id-type="pmcid">PMC6697256</pub-id><pub-id pub-id-type="pmid">31428741</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sbref1200"><person-group person-group-type="author"><name name-style="western"><surname>Arunkumar</surname><given-names>G</given-names></name><name name-style="western"><surname>Chandni</surname><given-names>R</given-names></name><name name-style="western"><surname>Mourya</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Outbreak investigation of Nipah virus disease in Kerala, India, 2018</article-title><source>J Infect Dis</source><volume>219</volume><year>2019</year><fpage>1867</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">30364984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiy612</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sbref1210"><person-group person-group-type="author"><name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name><etal/></person-group><article-title>Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India</article-title><source>Epidemiol Infect</source><volume>148</volume><year>2020</year><fpage>e90</fpage><pub-id pub-id-type="pmid">32321607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268820000825</pub-id><pub-id pub-id-type="pmcid">PMC7253795</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sbref1220"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guan</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Rapid and specific detection of all known Nipah virus strains' sequences with reverse transcription-loop-mediated isothermal amplification</article-title><source>Front Microbiol</source><volume>10</volume><year>2019</year><fpage>418</fpage><pub-id pub-id-type="pmid">30915049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.00418</pub-id><pub-id pub-id-type="pmcid">PMC6421284</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sbref1230"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>ES</given-names></name><name name-style="western"><surname>Spiropoulou</surname><given-names>CF</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name></person-group><article-title>Twenty years of Nipah virus research: where do we go from here?</article-title><source>J Infect Dis</source><volume>221</volume><issue>suppl 4</issue><year>2020</year><fpage>S359</fpage><lpage>S362</lpage><pub-id pub-id-type="pmid">32392321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiaa078</pub-id><pub-id pub-id-type="pmcid">PMC7213572</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sbref1240"><person-group person-group-type="author"><name name-style="western"><surname>Nikolay</surname><given-names>B</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh</article-title><source>medRxiv</source><year>2020</year><comment>published online Dec 8.</comment><pub-id pub-id-type="doi">10.1101/2020.12.06.20244871</pub-id><comment>(preprint).</comment><pub-id pub-id-type="pmid">34426025</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="other" id="sbref1250"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>Accelerated approval</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval" id="interrefs310">https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval</ext-link><year>2018</year></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="other" id="sbref1260"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Conditional marketing authorisation</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation" id="interrefs320">https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation</ext-link><year>2021</year></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="other" id="sbref1270"><person-group person-group-type="author"><collab>US Food and Drug Administartion</collab></person-group><article-title>CDER drug and biologic accelerated approvals based on a surrogate endpoint. As of December 31, 2020</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/88907/download" id="interrefs330">https://www.fda.gov/media/88907/download</ext-link><year>2020</year></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="other" id="sbref1280"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Ervebo</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo" id="interrefs340">https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo</ext-link><year>2021</year></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="other" id="sbref1290"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>Animal rule approvals</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/nda-and-bla-approvals/animal-rule-approvals" id="interrefs350">https://www.fda.gov/drugs/nda-and-bla-approvals/animal-rule-approvals</ext-link><year>2021</year></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="other" id="sbref1300"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>CDER drug and biologic animal rule approvals</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/145827/download" id="interrefs360">https://www.fda.gov/media/145827/download</ext-link><year>2021</year></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="other" id="sbref1310"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Zabdeno</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/zabdeno" id="interrefs370">https://www.ema.europa.eu/en/medicines/human/EPAR/zabdeno</ext-link><year>2021</year></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="other" id="sbref1320"><person-group person-group-type="author"><collab>EMA</collab></person-group><article-title>Mvabea</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/mvabea" id="interrefs380">https://www.ema.europa.eu/en/medicines/human/EPAR/mvabea</ext-link><year>2021</year></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="other" id="sbref1330"><person-group person-group-type="author"><collab>Directorate General of Drug Administration (DGDA)</collab></person-group><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dgda.gov.bd/" id="interrefs390">https://www.dgda.gov.bd/</ext-link><year>2013</year></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="other" id="sbref1340"><person-group person-group-type="author"><collab>Central Drugs Standard Control Organization</collab></person-group><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cdsco.gov.in/opencms/opencms/en/Home/" id="interrefs400">https://cdsco.gov.in/opencms/opencms/en/Home/</ext-link><year>2021</year></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="other" id="sbref1350"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Regulation and prequalification. Emergency use listing</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/teams/regulation-prequalification/eul" id="interrefs410">https://www.who.int/teams/regulation-prequalification/eul</ext-link><year>2021</year></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="other" id="sbref1360"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO publishes emergency use listing procedure and roadmap to make new medical products more readily available during health emergencies</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news/item/09-01-2020-emergency-use-listing-procedure-and-roadmap-health-emergencies" id="interrefs420">https://www.who.int/news/item/09-01-2020-emergency-use-listing-procedure-and-roadmap-health-emergencies</ext-link><year>2021</year></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sbref1370"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>J</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>S</given-names></name><name name-style="western"><surname>Eichberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens</article-title><source>NPJ Vaccines</source><volume>5</volume><year>2020</year><fpage>51</fpage><pub-id pub-id-type="pmid">32566261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0204-7</pub-id><pub-id pub-id-type="pmcid">PMC7295741</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sbref1380"><person-group person-group-type="author"><name name-style="western"><surname>Schrauf</surname><given-names>S</given-names></name><name name-style="western"><surname>Tschismarov</surname><given-names>R</given-names></name><name name-style="western"><surname>Tauber</surname><given-names>E</given-names></name><name name-style="western"><surname>Ramsauer</surname><given-names>K</given-names></name></person-group><article-title>Current efforts in the development of vaccines for the prevention of Zika and Chikungunya virus infections</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><fpage>592</fpage><pub-id pub-id-type="pmid">32373111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00592</pub-id><pub-id pub-id-type="pmcid">PMC7179680</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="other" id="sbref1390"><person-group person-group-type="author"><collab>FDA Guidance for Industry</collab></person-group><article-title>Expedited programs for serious conditions &#8211; drugs and biologics</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf" id="interrefs430">https://www.fda.gov/files/drugs/published/Expedited-Programs-for-Serious-Conditions-Drugs-and-Biologics.pdf</ext-link></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sbref1400"><person-group person-group-type="author"><name name-style="western"><surname>Beasley</surname><given-names>DWC</given-names></name><name name-style="western"><surname>Brasel</surname><given-names>TL</given-names></name><name name-style="western"><surname>Comer</surname><given-names>JE</given-names></name></person-group><article-title>First vaccine approval under the FDA Animal Rule</article-title><source>NPJ vaccines</source><volume>1</volume><year>2016</year><object-id pub-id-type="publisher-id">16013</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npjvaccines.2016.13</pub-id><pub-id pub-id-type="pmcid">PMC5707879</pub-id><pub-id pub-id-type="pmid">29263855</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="other" id="sbref1410"><person-group person-group-type="author"><collab>US Food and Drug Administartion</collab></person-group><article-title>Summary basis for regulatory action template for BioThrax</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wayback.archive-it.org/7993/20170723023407/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM474886.pdf" id="interrefs440">https://wayback.archive-it.org/7993/20170723023407/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM474886.pdf</ext-link><year>2015</year></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sbref1420"><person-group person-group-type="author"><name name-style="western"><surname>Snoy</surname><given-names>PJ</given-names></name></person-group><article-title>Establishing efficacy of human products using animals: the US food and drug administration's &#8220;animal rule&#8221;</article-title><source>Vet Pathol</source><volume>47</volume><year>2010</year><fpage>774</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">20551476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300985810372506</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="other" id="sbref1430"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Emergency use listing procedure. Version 13</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://extranet.who.int/pqweb/sites/default/files/documents/EUL-FINAL-13_12_2020.pdf" id="interrefs450">https://extranet.who.int/pqweb/sites/default/files/documents/EUL-FINAL-13_12_2020.pdf</ext-link><year>December 2020</year></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="other" id="sbref1440"><person-group person-group-type="author"><collab>Medicines &amp; Healthcare products Regulatory Agency</collab></person-group><article-title>Guidance on strain changes in authorised COVID-19 vaccines</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/access-consortium-guidance-on-strain-changes-in-authorised-covid-19-vaccines/guidance-on-strain-changes-in-authorised-covid-19-vaccines" id="interrefs460">https://www.gov.uk/government/publications/access-consortium-guidance-on-strain-changes-in-authorised-covid-19-vaccines/guidance-on-strain-changes-in-authorised-covid-19-vaccines</ext-link><year>2021</year></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="other" id="sbref1450"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group><article-title>Emergency use authorization for vaccines to prevent COVID-19. Guidance for industry. Document issued on Feb 22, 2021</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/media/142749/download" id="interrefs470">https://www.fda.gov/media/142749/download</ext-link></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="other" id="sbref1460"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf" id="interrefs480">https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf</ext-link><year>2021</year></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="other" id="sbref1470"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Addenum to considerations for evaluation of COVID-19 vaccines for prequalification or emergency use listing considerations for evaluation of modified COVID-19 vaccines. Points to consider for manufacturers of COVID-19 vaccines. Version 12. March, 2021</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://extranet.who.int/pqweb/sites/default/files/documents/Addendum_Evaluation_Modified_Covid-19%20Vaccine.pdf" id="interrefs490">https://extranet.who.int/pqweb/sites/default/files/documents/Addendum_Evaluation_Modified_Covid-19%20Vaccine.pdf</ext-link><year>2021</year></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="other" id="sbref1480"><person-group person-group-type="author"><collab>Wellcome Trust</collab></person-group><article-title>Low- and middle-income countries</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wellcome.org/grant-funding/guidance/low-and-middle-income-countries" id="interrefs500">https://wellcome.org/grant-funding/guidance/low-and-middle-income-countries</ext-link><year>2021</year></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="other" id="sbref1490"><person-group person-group-type="author"><collab>DMTC</collab></person-group><article-title>DMTC Annual Report 2020. MCM segment</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dmtc.com.au/wp-content/uploads/2020/12/MCM-Segment-DMTC_Annual-Report_2020.pdf" id="interrefs510">https://dmtc.com.au/wp-content/uploads/2020/12/MCM-Segment-DMTC_Annual-Report_2020.pdf</ext-link><year>2020</year></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sbref1500"><person-group person-group-type="author"><name name-style="western"><surname>Mahumud</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sarker</surname><given-names>AR</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>M</given-names></name><name name-style="western"><surname>Islam</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khan</surname><given-names>J</given-names></name><name name-style="western"><surname>Morton</surname><given-names>A</given-names></name></person-group><article-title>Distribution and determinants of out-of-pocket healthcare expenditures in Bangladesh</article-title><source>J Prev Med Public Health</source><volume>50</volume><year>2017</year><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">28372353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3961/jpmph.16.089</pub-id><pub-id pub-id-type="pmcid">PMC5398340</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="other" id="sbref1510"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Out-of-pocket payments, user fees and catastrophic expenditure</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/health_financing/topics/financial-protection/out-of-pocket-payments/en/" id="interrefs520">https://www.who.int/health_financing/topics/financial-protection/out-of-pocket-payments/en/</ext-link></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sbref1520"><person-group person-group-type="author"><name name-style="western"><surname>Crager</surname><given-names>SE</given-names></name></person-group><article-title>Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways</article-title><source>Am J Public Health</source><volume>108</volume><year>2018</year><fpage>S414</fpage><lpage>S420</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2014.302236</pub-id><pub-id pub-id-type="pmcid">PMC4202949</pub-id><pub-id pub-id-type="pmid">25211753</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="other" id="sbref1530"><person-group person-group-type="author"><collab>Medecins Sans Frontieres Access Campaign</collab></person-group><article-title>Giving developing countries the best shot: an overview of vaccine access and R&amp;D</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://msfaccess.org/giving-developing-countries-best-shot-overview-vaccine-access-and-rd" id="interrefs530">https://msfaccess.org/giving-developing-countries-best-shot-overview-vaccine-access-and-rd</ext-link><year>2020</year></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="other" id="sbref1540"><person-group person-group-type="author"><collab>Coalition for Epidemic Preparedness Innovations</collab></person-group><article-title>Why we exist</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cepi.net/about/whyweexist/" id="interrefs540">https://cepi.net/about/whyweexist/</ext-link><year>2021</year></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="other" id="sbref1550"><person-group person-group-type="author"><collab>PATH</collab></person-group><article-title>The Meningitis Vaccine Project: a groundbreaking partnership</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.path.org/articles/about-meningitis-vaccine-project/" id="interrefs550">https://www.path.org/articles/about-meningitis-vaccine-project/</ext-link><year>2015</year></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="other" id="sbref1560"><person-group person-group-type="author"><collab>Gilead</collab></person-group><article-title>Voluntary licensing agreements for remdesivir</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir" id="interrefs560">https://www.gilead.com/purpose/advancing-global-health/covid-19/voluntary-licensing-agreements-for-remdesivir</ext-link><year>2021</year></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="other" id="sbref1570"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>In the COVID-19 vaccine race, we either win together or lose together</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news/item/10-02-2021-in-the-covid-19-vaccine-race-we-either-win-together-or-lose-together" id="interrefs570">https://www.who.int/news/item/10-02-2021-in-the-covid-19-vaccine-race-we-either-win-together-or-lose-together</ext-link><year>Feb 10, 2021</year></element-citation></ref></ref-list><sec id="sec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="para560">
<supplementary-material content-type="local-data" id="ecomp10" position="float" orientation="portrait"><caption><title>Supplementary appendix</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ceack10"><sec><title>Acknowledgments</title><p>We thank Amol Chaudhari, Gabrielle Breugelmans, and Georges Thiry for reviewing the manuscript, and Julia Granerod for providing scientific writing support.</p></sec></ack><ack><title>Contributors</title><p>RGR, NT, NGC, ACS, MLJ, DY, EM, and TTL contributed to conceptualidation of the study. RGR did the literature search for the vaccines section, NGC did the search for the small molecules section, and TTL did the search for the monoclonal antibodies section. RGR verified the data in the small molecules section, NGC verified the data in the monoclonal antibodies section, and TTL verified the data in the vaccines section. RGR, NGC, ACS, MLJ, DY, AH, EM, and TTL contributed to drafting of the manuscript. NT, MLJ, DY, and AH critically reviewed the scientific content. All authors reviewed and approved the final version.</p></ack></back></article></pmc-articleset>